Способ персонифицированной неоадъювантной внутриартериальной химиотерапии рака желудка

Изобретение относится к медицине, а именно к онкологии, и может быть использовано для персонифицированной неоадъювантной внутриартериальной химиотерапии рака желудка. Способ включает введение химиопрепаратов селективно в чревный ствол, при этом в чревный ствол вводят 50% дозы химиопрепаратов и суперселективно 50% дозы химиопрепаратов в левую желудочную, гастродуоденальную или селезеночную артерию, в зависимости от преимущественного поражения отдела желудка и смежных органов. Использование изобретения позволяет повысить операбельность и эффективность лечения, достичь значимого уменьшения размеров опухоли и локорегионарных метастазов за счет проведения внутриартериальной химиотерапии селективно в чревный ствол и суперселективно в соответствующую артерию с учетом локализации опухоли в анатомической области желудка в пропорции по 50% дозы на селективное и суперселективное введение препаратов. 2 пр.

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ

Изобретение относится к фармацевтической композиции для перорального введения, которая включает суспензию 0,5-50 мас.% от общей массы композиции комплекса платины (ОС-6-43) бис(ацетато)-(1-адамантиламино)амин-дихлорплатина(IV) (LA-12) с размером частиц менее 100 мкм в фармацевтически приемлемом растительном, животном, минеральном, синтетическом или полусинтетическом масле и/или маслянистом веществе и фармацевтически приемлемый эксципиент. Композиция по изобретению может быть использована в качестве лекарства для терапии опухолевых заболеваний. Изобретение обеспечивает стабильную композицию с высоким содержанием комплекса четырехвалентной платины. 9 з.п. ф-лы.

АНТАГОНИСТЫ WNT И СПОСОБЫ ЛЕЧЕНИЯ И ТЕСТИРОВАНИЯ

Изобретение относится к области биотехнологии, конкретно к антагонистам Wnt, и может быть использовано в медицине. С использованием сигнальной последовательности получают Wnt-связывающие полипептиды на основе домена Fri из FZD8 человека и Fc-фрагмента. Полученные полипептиды используются в составе фармацевтической композиции для лечения заболевания, связанного с активацией пути передачи сигнала Wnt, например рака. Изобретение позволяет повысить гомогенность смеси Wnt-связывающих полипептидов при получении их путем рекомбинантного продуцирования. 17 н. и 15 з.п. ф-лы, 21 ил., 5 табл., 17 пр.

АКТИВАЦИЯ ПРОКАСПАЗЫ-3 С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ

Группа изобретений относится к химико-фармацевтической промышленности и представляет собой композицию для терапии рака путем активации прокаспазы, содержащую соединение РАС-1:; второе активное средство, выбранное из: бортезомиб, ставроспорин, доксорубицин, тамоксифен, цисплатин, карбоплатин или паклитаксел; и фармацевтически приемлемый разбавитель, наполнитель и/или носитель, где концентрация РАС-1 составляет от 2 мкМ до 50 мкМ, а концентрация второго активного средства составляет от 1 нМ до 1 мМ. Также изобретения включают в себя способы индукции апоптоза в раковых клетках и подавления роста и/или пролиферации раковых клеток для лечения рака путем активации прокаспазы, включающие в себя воздействие на эти раковые клетки эффективным количеством композиции, описанной выше. Группа изобретений обеспечивает синергетический эффект активных агентов в композиции, что приводит к индуцированию апоптотической смерти раковых клеток, и проявляет более слабые нейротоксические эффекты, чем другие соединения ...

ПОЛИМЕРНЫЙ КОНЪЮГАТ ГЕКСАКООРДИНИРОВАННОГО КОМПЛЕКСА ПЛАТИНЫ

Изобретение относится к полимерным конъюгатам гексакоординированного комплекса платины. Предложен полимерный конъюгат гексакоординированного комплекса платины, в котором гексакоординированный комплекс платины, содержащий галогены и гидроксильные группы в аксиальных положениях, напрямую или через спейсеры связаны с карбоксильными группами боковой цепи блок-сополимера, содержащего полиэтиленгликолевый структурный фрагмент и фрагмент полиаспарагиновой кислоты или фрагмент полиглутаминовой кислоты. Технический результат – предложенный конъюгат эффективно высвобождает высокоактивный комплекс платины в восстановительных условиях, в том числе в клетках. 6 н. и 10 з.п. ф-лы, 2 ил., 7 табл., 21 пр.

СПОСОБЫ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ

Группа изобретений относится к медицине, а именно к онкологии, и может быть использована для получения лекарственного средства для лечения пролиферативного заболевания у индивидуума. Для этого применяют композицию, содержащую наночастицы таксана и белка-носителя в комбинации с эффективным количеством по меньшей мере одного другого средства, выбранного из децитабина и азацитидина. Причем азацитидин пригоден для перорального введения. Также предложен набор для лечения пролиферативного заболевания. Группа изобретений обеспечивает лечение заболеваний за счет синергетического действия композиции, содержащей наночастицы таксана и белка-носителя в комбинации с децитабином. 2 н. и 39 з.п. ф-лы, 3 табл., 7 ил., 11 пр.

AXL-АНТИТЕЛА

Настоящее изобретение относится к области иммунологии. Предложены моноклональные антитела, которые связываются с внеклеточным доменом рецепторной тирозинкиназы AXL и которые, по меньшей мере, частично ингибируют активность AXL, а также их антигенсвязывающие фрагменты. Также рассмотрена выделенная молекула нуклеиновой кислоты, клетка-хозяин и способ получения моноклонального антитела и его антигенсвязывающего фрагмента, а также применение моноклонального антитела или его антигенсвязывающего фрагмента для изготовления лекарственного средства, фармацевтические композиции, способ диагностики и способ профилактики или лечения состояния, связанного с экспрессией, сверхэкспрессией и/или гиперактивностью AXL. Настоящее изобретение может найти дальнейшее применение в терапии и диагностике заболеваний, связанных с AXL. 11 н. и 12 з.п. ф-лы, 20 ил., 24 пр., 3 табл.

ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО

Изобретение относится к области медицины и касается противоопухолевого средства. Изобретение заключается в том, что средство включает производное стильбена и координационное соединение платины в качестве активных ингредиентов и фармацевтически приемлемые носители. Изобретение обеспечивает при использовании этих двух типов активных ингредиентов в сочетании улучшение противоопухолевой активности фармацевтического препарата, достигая синергического эффекта. При этом противоопухолевая активность, свойственная производному стильбена, дополнительно увеличивается, давая противоопухолевое средство с улучшенной эффективностью, которая является особенно адекватной для лечения злокачественных опухолей. 2 с. и 7 з.п.ф-лы, 6 табл.

ФАРМАЦЕВТИЧЕСКАЯ КОМБИНАЦИЯ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ХЕМОСЕНСИБИЛИЗАЦИИ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ПРОТИВОРАКОВЫМ СРЕДСТВАМ

Изобретение относится к медицине, в частности к молекулярной и экспериментальной онкологии, и представляет собой фармацевтическую комбинацию для одновременного, раздельного или последовательного введения, которая содержит ингибитор сайта фосфорилирования на субстратах СК2, который включает пептид Р15 (CWMSPRHLGTC) вместе с цитостатическим веществом, фармацевтически приемлемо смешанным с соответствующими переносчиками. Изобретение обеспечивает повышение терапевтического индекса текущих цитотоксических веществ, при помощи уменьшения эффективной дозы и естественной токсичности, проявляемой этим видом лекарственных средств, а также обход химической устойчивости опухоли по отношению к традиционным цитотоксическим веществам, 4 н. и 8 з.п. ф-лы, 4 табл., 2 ил.

ЛЕЧЕНИЕ РАКА ЛЕГКОГО С ПОМОЩЬЮ КОМБИНАЦИИ АНТИТЕЛА ПРОТИВ PD-1 И ДРУГОГО ПРОТИВОРАКОВОГО СРЕДСТВА

Группа изобретений относится к медицине, а именно к онкологии, и может быть использована при лечении рака легкого. Способ по изобретению включает введение субъекту комбинации ниволумаба и двухкомпонентной химиотерапии на основе платинового препарата (PT-DC), причем PT-DC представляет собой комбинацию гемцитабина в дозе 1250 мг/ми цисплатина в дозе 75 мг/м; комбинацию пеметрекседа в дозе 500 мг/ми цисплатина в дозе 75 мг/м; или комбинацию паклитаксела в дозе 200 мг/ми карбоплатина в дозе, обеспечивающей желаемую область под кривой 6 мг/мл/мин (AUC6), причем PT-DC вводится одновременно с ниволумабом в течение 4 доз ниволумаба, с последующим повторным введением ниволумаба отдельно. Набор по изобретению включает дозы ниволумаба и PT-DC и инструкции по их применению. Использование изобретений позволяет повысить противоопухолевую активность ниволумаба, повысить общую выживаемость пациентов, снизить опухолевую массу под действием комбинации. 2 н. и 14 з.п. ф-лы, 23 ил., 37 табл., 6 пр.

Фармацевтическая композиция на основе соединения палладия

Изобретение относится к фармацевтической композиции на основе соединения палладия. Указанная композиция содержит ацидокомплекс палладия формулы: (СНNO)[PdCI] в концентрации 0,2% в 0,9% водном растворе хлорида натрия. Изобретение обеспечивает выраженное противоопухолевое и антиметастатическое действие при курсовом парентеральном введении эффективных доз. 4 з.п. ф-лы, 13 табл., 6 пр.

КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ АНТИТЕЛ К КЛАУДИНУ 18.2 ДЛЯ ЛЕЧЕНИЯ РАКА

Группа изобретений относится к медицине и касается способа лечения или предотвращения ракового заболевания, где раковые клетки экспрессируют CLDN18.2, включающего введение пациенту антитела, обладающего способностью связываться с CLDN18.2, в комбинации со средством, стимулирующим γδ Т-клетки и интерлейкин-2, где средство, стимулирующее γδ Т-клетки, представляет собой бисфосфонат. Группа изобретений также касается медицинского препарата для лечения или предотвращения ракового заболевания, содержащего указанные вещества; набора для лечения или предотвращения ракового заболевания. Группа изобретений обеспечивает значительное увеличение общей ADCC-активности. 3 н. и 32 з.п. ф-лы, 26 ил., 1 табл., 17 пр.

СПОСОБ ПОЛУЧЕНИЯ ПОЛИМЕРИЗОВАННЫХ КООРДИНАЦИОННЫХ СОЕДИНЕНИЙ КОМПЛЕКСА ПЛАТИНЫ

Изобретение относится к способу получения конъюгата блок-сополимера и комплекса платины, который может быть использован в качестве противоопухолевого средства. Способ включает взаимодействие в водной среде комплекса диаквоплатины или бис(нитрато)платины в смеси с дигалогеноплатиной с блок-сополимером, формулы (1) или (2): ! ! ! где R1- водород или C1-C12-алкил, L1 и L2 - соединительные группы, R3 - водород, защитная группа для аминогруппы, гидрофобная или полимеризуемая группа, R4 - гидрокси-, карбокси- или гидрофобная группа, R5 - водород, ион щелочного металла или защитная группа для карбоксильной группы, m=5-20000, n=10-60, при условии, что R5 - водород или ион щелочного металла составляет 50% и более в n звеньях. Предложенный способ обеспечивает получение не содержащего иона серебра конъюгата, раствор которого обладает более узким распределением частиц по размеру. 2 н. и 15 з.п. ф-лы, 11 ил.

ПРОИЗВОДНОЕ БЕНЗОХИНОНА Е3330 В КОМБИНАЦИИ С ХИМИОТЕРАПЕВТИЧЕСКИМИ АГЕНТАМИ ДЛЯ ЛЕЧЕНИЯ РАКА И АНГИОГЕНЕЗА

Предложен способ подавления физиологических нарушений, связанных с измененным ангиогенезом, выбранных из ретинопатии, диабетической ретинопатии, макулярной дегенерации, ретролентальной фиброплазии, возрастной макулярной дегенерации, опухоли поджелудочной железы и глиомы, включающий введение эффективного количества 3-[(5-(2,3-диметокси-6-метил-1,4-бензохинонил)]-2-нонил-2-пропеновой кислоты (Е3330) или ее фармацевтически приемлемых солей или сольватов. Показано снижение количества VGEF и пролиферации эндотелиальных клеток сетчатки под действием Е3330 даже в присутствии фактора роста фибробластов, как в условиях нормоксии, так и гипоксии за счет ингибирования окислительно-восстановительной активности Ape1/Ref-1. Последнее, а также снижение активности HIF-1α, NFκβ, АР-1 под действием Е3330 и подавление за счет этого роста, выживаемости, миграции и метастазирования опухолевых клеток сопровождалось отсутствием существенного подавления роста нормальных клеток (гемопоэтических эмбриональных клеток ...

СПОСОБ ИНДИВИДУАЛИЗИРОВАННОЙ ВНУТРИАРТЕРИАЛЬНОЙ ИНФУЗИИ ХИМИОПРЕПАРАТА ПРИ ЛЕЧЕНИИ ПЛОСКОКЛЕТОЧНОГО РАКА ГОЛОВЫ И ШЕИ

Изобретение относится к медицине, а именно к оторинолярингологии и онкологии. Выполняют ангиографическое исследование непосредственно в рентгеноперационной, перед процедурой введения препарата платины. Выявляют доминантный сосуд, кровоснабжающий опухоль. Проводят его селективную катетеризацию и определяют объемную скорость кровотока. Препарат платины вводят со скоростью, равной или не более чем на 16,7% превышающей объемную скорость кровотока. Объем вводимого препарата рассчитывают из соотношения 75-100 мг/мплощади поверхности тела пациента. Затем в тот же сосуд вводят 5-фторурацил со скоростью инфузии, равной или не более чем на 16,7% превышающей собственную объемную скорость кровотока в этом сосуде в объеме не менее 250 мл. Способ позволяет снизить выраженность токсических реакций на химиотерапевтическое лечение, устранить осложнения и летальные исходы, связанные с проведением самого лечения, устранить патологические изменений функции почек повышением общей одногодичной выживаемости пациентов ...

Способ комбинированного лечения немелкоклеточного рака легких II-III стадии

Изобретение относится к медицине, онкологии, предназначено для комбинированного лечения немелкоклеточного рака легкого (НМРЛ) II-III стадии. Проводят 2 курса химиотерапии по схеме паклитаксел 175 мг/ми карбоплатин AUC 6 в 1-й и 20-й дни. При этом лучевую терапию начинают с 4 дня по 2 Гр × 1 раз в день, 5 дней в неделю, 4 недели до суммарной очаговой дозы 40 Гр на фоне локальной гипертермии (ЛГТ). ЛГТ проводят 2 раза в неделю, всего 10 сеансов, за 40 мин до облучения или введения химиопрепаратов в течение 40-60 мин при температуре от 42,5 до 44°C. Через 4 недели после окончания термохимиолучевой терапии выполняют радикальное хирургическое лечение. Способ обеспечивает улучшение непосредственных результатов лечения НМРЛ II-III стадии за счет повышения частоты регрессии и резектабельности опухоли, снижения количества осложнений, достижения надежного локорегионарного контроля и профилактики развития гематогенных метастазов. 1 пр.

СТАБИЛИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ АНГИОПОЭТИНА-2 И ИХ ПРИМЕНЕНИЕ

Изобретение относится к области иммунологии. Представлено антитело против ангиопоэтина-2 (Ang-2), причем указанное антитело включает вариабельную область тяжелой цепи SEQ ID No:7 (MEDI5) и вариабельную область легкой цепи, выбранную из SEQ ID No:3 (MEDI1); SEQ ID No:4 (MEDI2); SEQ ID No:5 (MEDI3); и SEQ ID No:6 (MEDI4). Раскрыта выделенная нуклеиновая кислота, кодирующая указанное антитело. Описана композиция для применения в ингибировании ангиогенеза раковой опухоли у животного, нуждающегося в этом, содержащая указанное выделенное антитело в терапевтически эффективном количестве и эксципиент. Предложенные вариантные антитела обладают повышенной стабильностью при хранении по сравнению с исходным антителом 3.19.3, из которого они получены, и способны конкурировать с Tie-2 за связывание с Ang-2. 3 н. и 9 з.п. ф-лы, 17 ил., 15 табл., 13 пр.

СРЕДСТВО, УЛУЧШАЮЩЕЕ ПРОТИВООПУХОЛЕВЫЙ ЭФФЕКТ, СОДЕРЖАЩЕЕ ЛИПОСОМАЛЬНОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ОКСАЛИПЛАТИН, И ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ЛИПОСОМАЛЬНОЕ СРЕДСТВО

Группа изобретений относится к противоопухолевому средству и средству, усиливающему противоопухолевый эффект, которое комбинированно содержит липосомальное средство, полученное посредством инкапсулирования оксалиплатина в липосому, и комбинированное лекарственное средство, содержащее тегафур, гимерацил и отерацил калия. Липосома в заявленных средствах состоит из дипальмитоилфосфатидилхолина, холестерина и 1,2-дистеароил-sn-глицеро-3-фосфоэтаноламин-n-[метокси(полиэтиленгликоль)-2000; или гидрогенизированного фосфатидилхолина соевых бобов, холестерина и 1,2-дистеароил-sn-глицеро-3-фосфоэтаноламин-n-[метокси(полиэтиленгликоль)-2000; или дипальмитоилфосфатидилхолина, холестерина и 1,2-дистеароил-sn-глицеро-3-фосфоэтаноламин-полиглицерин. Изобретение также относится к применению липосомального средства, описанного выше, для получения противоопухолевого средства и для усиления противоопухолевой активности комбинированного лекарственного средства, содержащего тегафур, гимерацил и отерацил калия ...

Способ комбинированного лечения метастатического колоректального рака у больных с резектабельными метастазами в печени и при отсутствии мутаций в генах KRAS и BRAF

Изобретение относится к медицине, а именно к онкологии, и может быть использовано для комбинированного лечения метастатического колоректального рака у больных с резектабельными метастазами в печени и при отсутствии мутаций в генах KRAS и BRAF. Способ включает введение цетуксимаба 500 мг/м2 внутривенно капельно в 1 день, иринотекана внутривенно капельно в 1 день, оксалиплатина 85 мг/м2 внутривенно капельно в 1 день, инфузию лейковорина 200 мг/м2 внутривенно капельно в 1 день и 5-фторурацила внутривенно капельно. Проводят три курса предоперационного лечения, при этом инфузию лейковорина проводят в 1 и 2 дни по 200 мг/м2, доза иринотекана составляет 165 мг/м2, инфузию 5-фторурацила в дозе 3200 мг/м2 проводят в течение 46 часов, перерыв между курсами составляет 12 дней. После завершения предоперационного лечения при наличии объективного ответа опухоли выполняют симультанную радикальную операцию на первичной опухоли и на метастатических очагах в печени R0, в послеоперационном периоде проводят ...

Способ персонализированного комбинированного лечения больных местно-распространенным немелкоклеточным раком легкого II - III стадии

Изобретение относится к медицине, а именно к онкологии, и может быть использовано для персонализированного комбинированного лечения немелкоклеточного рака легкого II-III стадии. Выполняют радикальную анатомическую резекцию с медиастинальной ипсилатеральной лимфодиссекцией с интраоперационной лучевой терапией с разовой дозой РОД 10,0 Гр. В послеоперационном периоде, при уровне экспрессии гена монорезистентности ERCC1 менее 1,5 проводят адъювантную химиотерапию с использованием карбоплатина в дозе по AUC6 в комбинации с цитостатиком, выбор которого осуществляют следующим образом: при уровне RRM1 или TYMS менее 1,5, АВСС5 менее 1, проводят адъювантную химиотерапию с использованием карбоплатина и гемцитабина; при уровне ТОР1 более 3 проводят адъювантную химиотерапию с использованием карбоплатина и иринотекана; при уровне TUBB3 1,5-2,5 проводят адъювантную химиотерапию с использованием карбоплатина и винорелбина; при уровне ТОР2а более 3 проводят адъювантную химиотерапию с использованием карбоплатина ...

Антимикробная композиция на основе силоксанового каучука

Изобретение относится к медицине и фармацевтической промышленности и представляет собой антибактериальную композицию, предназначенную для изготовления имплантируемых изделий медицинского назначения на основе полидиметилметилвинилсилоксанового каучука, включающую аэросил, антиструктурирующую добавку, кремнегидрид, платиновый катализатор и антимикробную добавку, отличающуюся тем, что в качестве антимикробной добавки композиция содержит рифампицин, причем компоненты в композиции находятся в определенном соотношении, в масс.ч. Изобретение обеспечивает высокую биосовместимость и продолжительный антимикробный эффект. 2 табл., 1 пр.

ПРОТИВООПУХОЛЕВАЯ, АНТИБАКТЕРИАЛЬНАЯ И АНТИВИРУСНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ЕЕ ВАРИАНТЫ)

Композиция по первому варианту содержит азотнокислое серебро, гексаметилентетрамин, тиосульфат натрия, альфа-аспарагиновую кислоту или аспарагин, никотиновую кислоту и воду в указанных в формуле изобретения количествах. Композиция по второму варианту содержит азотнокислое серебро, гексаметилентетрамин или имидазол, имидазолсодержащее соединение платины цис-[Pt(NH3)2Im2]Cl3 или цис-[Pt(NH2OH)2Im2]Cl2, альфа-аспарагиновую кислоту или аспарагин, никотиновую кислоту и воду в указанных в формуле изобретения количествах. Композиции по изобретению обладают повышенной противоопухолевой активностью с одновременным антибактериальным и антивирусным воздействием на организм. 2 н.п. ф-лы, 3 ил., 6 табл.

СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ С BRCA-АССОЦИИРОВАННЫМ ТРИЖДЫ НЕГАТИВНЫМ МЕСТНОРАСПРОСТРАНЕННЫМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

Изобретение относится к области медицины, а именно к онкологии, и может быть использовано для лечения больных с BRCA-ассоциированным трижды негативным местнораспространенным раком молочной железы (ТНРМЖ). Способ включает неоадъювантную полихимиотерапию (НАХТ) с клинической ее оценкой и последующим хирургическим лечением. На этапе НАХТ выполняют 4 цикла лекарственной терапии препаратами митомицин медак 10 мг/м2 в сочетании с цисплатином 100 мг/м2 1 раз в 28 дней с клинической оценкой НАХТ, представляющей собой ОФЭКТ-КТ молочных желез, маммографию и УЗИ молочных желез с эластографией, после 2 и 4 циклов. Использование изобретения позволяет увеличить частоту достижения полного патологического ответа (pCR) у больных с BRCA-ассоциированным местнораспространенным ТНРМЖ при 4-кратном сокращении курса системной терапии. 6 ил., 3 пр.

Способ лечения перитонеального канцероматоза при раке яичников

Изобретение относится к области медицины, а именно к онкологии. Выполняют циторедукцию путем осуществления нижнесрединной лапаротомии с продлением разреза выше пупка. Удаляют большой сальник, осуществляют экстирпацию матки с придатками, удаляют все резектабельные метастазы. Затем ушивают культю влагалища, осуществляют перитонизацию. После чего выполняют гемостаз в опухолевом ложе путем коагуляции и наложения лигатур на кровоточащие сосуды. Затем осуществляют видеоэндоскопический этап, для чего производят установку двух троакаров: один устанавливают в эпигастральной области, а другой в гипогастральной. Герметично ушивают лапаротомную рану без установки дренажей. После герметизации брюшной полости через троакар подают углекислый газ в брюшную полость, формируют карбоксиперитонеум с интраперионеальным давлением 12-15 мм рт.ст. При этом через троакар в эпигастральной области вводят лапароскоп, через троакар в гипогастрии вводят форсунку, которую соединяют с инжектором. Посредством инжектора ...

Способ комбинированного лечения рака прямой кишки при поражении верхнеампулярного отдела прямой кишки с промежуточным и умеренным риском развития локорегионарного рецидива

Изобретение относится к медицине, а именно к онкологии, и касается комбинированного лечения рака прямой кишки при поражении верхнеампулярного отдела прямой кишки с промежуточным и умеренным риском развития локорегионарного рецидива. Для этого проводят 3 курса химиотерапии путем введения оксалиплатина и капецитабина. Инфузию оксалиплатина начинают в 08-00 и продолжают в течение 4 часов, а капецитабин принимают с интервалом в 12 часов, с 20-00 в 1-й день до 08-00 в 15-й день, перерыв между курсами химиотерапии составляет 6 дней. Такой режим введения наряду с эффективным воздействием на опухоль обеспечивает снижение побочных эффектов химиотерапии. 2 пр.

СПОСОБ МОДИФИЦИРОВАННОГО ХИМИОЛУЧЕВОГО ЛЕЧЕНИЯ РАКА ПРЯМОЙ КИШКИ

Изобретение относится к медицине, а именно к онкологии, и может быть использовано для модифицированного химиолучевого лечения рака прямой кишки. Для этого выполняют катетеризацию верхней прямокишечной артерии через бедренную артерию, в которую вводят цисплатин 50 мг на 5% глюкозе 50 мл и фторурацил 500 мг в течение 30 минут. Со следующих суток проводят короткий курс крупнофракционной лучевой терапии - 5 сеансов по 5 Гр на первичную опухоль и регионарные лимфоузлы. До начала каждого сеанса лучевой терапии внутривенно капельно вводят 100 мл озонированного физиологического раствора с концентрацией озона 1000 мкг/л в течение 10 минут, через 5 минут вводят фторурацил 500 мг на растворе натрия хлорида 0,9% 200 мл в течение 30 минут. После 30-минутной экспозиции проводят сеанс лучевой терапии. Через 4 недели после окончания курса модифицированного химиолучевого лечения рака прямой кишки выполняют оперативное вмешательство на прямой кишке - резекцию или экстирпацию прямой кишки в стандартном объеме ...

Способ лечения неоперабельного немелкоклеточного рака легкого

Изобретение относится к медицине, а именно к хирургии и онкологии, и может быть использовано для лечения неоперабельного немелкоклеточного рака легкого. Для этого выполняют диагностическую видеоторакоскопию со стороны пораженного легкого, фенестрацию медиастинальной плевры на уровне среднего этажа переднего средостения. Далее с использованием эндоскопического инструмента выполняют отслаивание медиастинальной плевры от подлежащей клетчатки, начиная от сформированной фенестры по направлению к верхнему этажу средостения на протяжении всего визуального контролируемого участка. Сформированную в медиастинальной плевре фенестру не ушивают. После этого через сформированное окно в средостение устанавливают перфорированный силиконовый катетер, рабочую часть которого располагают на протяжении всей выделенной плевры, а дистальную его часть выводят на поверхность передней грудной стенки в пятом межреберье по парастернальной линии и фиксируют к коже. Начиная со 2-х суток после операции, через установленный ...

Способ комбинированного лечения метастатического колоректального рака у больных с резектабельными метастазами в печени при отсутствии мутаций в генах KRAS

Изобретение относится к области медицины, а именно к онкологии, и может быть использовано для комбинированного лечения метастатического колоректального рака у больных с резектабельными метастазами в печени при отсутствии мутаций в генах KRAS. Способ включает проведение курсов противоопухолевой лекарственной терапии, в первый день внутривенно капельно вводят: иринотекан в дозе 165 мг/м2, оксалиплатин в дозе 85 мг/м2, цетуксимаб в дозе 500 мг/м2, капецитабин перорально ежедневно в два приема в дозе 2500 мг/м2 с 1 по 14 дни. Перерыв между курсами составляет 7 дней, проводят 3 курса предоперационного лечения, радикальную операцию и 3 курса адъювантного лечения. Использование изобретения позволяет достичь улучшения результатов комбинированного лечения метастатического колоректального рака у больных с резектабельными метастазами в печени при отсутствии мутаций в генах KRAS за счет повышения частоты объективных ответов опухоли и снижения количества нежелательных явлений при проведении лекарственного ...

Способ комбинированного лечения метастатического колоректального рака у больных с резектабельными метастазами в печени

Изобретение относится к медицине, а именно к онкологии, и может быть использовано для комбинированного лечения метастатического колоректального рака (мКРР) у больных с резектабельными метастазами в печени. Способ включает проведение курсов противоопухолевой лекарственной терапии с использованием иринотекана в дозе 165 мг/м2 внутривенно капельно в 1 день, оксалиплатина в дозе 85 мг/м2 внутривенно капельно в 1 день, капецитабина перорально ежедневно в два приема, применяют 3 курса предоперационного лечения по вышеуказанной схеме, радикальную операцию и 3 курса адъювантного лечения, при этом прием капецитабина в дозе 2500 мг/м2 проводят с 1 по 14 дни, перерыв между курсами составляет 7 дней. Использование изобретения позволяет достичь улучшения результатов комбинированного лечения мКРР у больных с резектабельными метастазами в печени за счет повышения частоты объективных ответов опухоли и снижения количества нежелательных явлений при проведении лекарственного противоопухолевого лечения, увеличения ...

НОВАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ПОБОЧНЫХ ЭФФЕКТОВ ПРОТИВОРАКОВОЙ ТЕРАПИИ

... 1. Композиция, предпочтительно фармацевтическая, содержащая по меньшей мере один цитотоксический агент и по меньшей мере оксим холест-4-ен-3-она или одно из его производных. ! 2. Композиция по п.1, отличающаяся тем, что она содержит по меньшей мере !соединение формулы I ! ! в которой ! X означает группу =N-OH, ! R означает группу, выбранную из ! ! A означает атом водорода или вместе с B означает углерод-углеродную связь, ! B означает атом водорода, гидроксигруппу или вместе с A означает углерод-углеродную связь, ! C означает атом водорода, кетоновую группу или оксимовую группу (=NOH), или вместе с D означает углерод-углеродную связь, !D означает атом водорода или вместе с C означает углерод-углеродную связь, ! E означает атом водорода или вместе с F означает углерод-углеродную связь, ! F означает атом водорода или вместе с E означает углерод-углеродную связь, ! или одну из его солей присоединения c фармацевтически приемлемыми кислотами, или один из его сложных эфиров, или одну из солей ...

ПРОИЗВОДНОЕ БЕНЗОХИНОНА Е3330 В КОМБИНАЦИИ С ХИМИОТЕРАПЕВТИЧЕСКИМИ АГЕНТАМИ ДЛЯ ЛЕЧЕНИЯ РАКА И АНГИОГЕНЕЗА

... 1. Способ подавления физиологических нарушений, связанных с измененным ангиогенезом, включающий введение нуждающемуся субъекту эффективного количества агента, селективно ингибирующего окислительно-восстановительную активность Ape1/Ref-1. ! 2. Способ по п.1, где указанным агентом является Е3330 или его фармацевтически приемлемая соль. ! 3. Способ по п.1, где указанное нарушение выбрано из онкологического заболевания, сердечно-сосудистого заболевания, хронического воспалительного заболевания, ревматоидного артрита, диабетической ретинопатии, макулярной дегенерации, ретролентальной фиброплазии, идиопатического фиброза легких, острого респираторного дистресс-синдрома взрослых, астмы, эндометриоза, псориаза, келоидов и системного склероза. ! 4. Способ по п.3, где указанным нарушением является рак. ! 5. Способ по п.4, где указанным агентом является Е3330, или его фармацевтически приемлемая соль, или сольват. ! 6. Способ по п.5, где указанному субъекту вводится по меньшей мере один дополнительный ...

КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ АНТИТЕЛ К КЛАУДИНУ 18.2 ДЛЯ ЛЕЧЕНИЯ РАКА

... 1. Способ лечения или предотвращения ракового заболевания, включающий введение пациенту антитела, обладающего способностью связываться с CLDN18.2, в комбинации со средством, стимулирующим γδ Т-клетки.2. Способ по п. 1, согласно которому γδ Т-клетки являются Vγ9Vδ2 Т-клетками.3. Способ по п. 1 или 2, согласно которому средство, стимулирующее γδ Т-клетки, является бисфосфонатом.4. Способ по п. 1 или 2, согласно которому средство, стимулирующее γδ Т-клетки, является азотсодержащим бисфосфонатом (аминобисфосфонатом).5. Способ по п. 1 или 2, согласно которому средство, стимулирующее γδ Т-клетки, выбирают из группы, состоящей из золедроновой кислоты, клодроновой кислоты, ибандроновой кислоты, памидроновой кислоты, ризедроновой кислоты, минодроновой кислоты, олпадроновой кислоты, алендроновой кислоты, инкадроновой кислоты и их солей.6. Способ по п. 1 или 2, согласно которому средство, стимулирующее γδ Т-клетки, вводится в комбинации с интерлейкином-2.7. Способ по п. 1 или 2, согласно которому ...

МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ДЛЯ ЛЕЧЕНИЯ ОПУХОЛЕЙ

... 1. Применение гуманизированного моноклонального антитела или его фрагмента, причем указанное антитело или его фрагмент включает вариабельный участок легкой цепи, выбранный из группы, состоящей из: BATRκA (SEQ ID NO: 15), BATRκB (SEQ ID NO: 16), BATRκC (SEQ ID NO: 17) и BATRκD (SEQ ID NO: 18), и вариабельный участок тяжелой цепи, выбранный из группы, состоящей из: BATRHA (SEQ ID NO: 20), BATRHB (SEQ ID NO: 21), BATRHC (SEQ ID NO: 22), BATRHD (SEQ ID NO: 23) и BATRHE (SEQ ID NO: 24), для снижения вероятности рецидива опухоли или предотвращения рецидива опухоли.2. Применение по п. 1, отличающееся тем, что гуманизированное моноклональное антитело включает вариабельные участки, выбранные из группы, состоящей из: BATRHA/BATRκA (SEQ ID NO: 20/SEQ ID NO: 15), BATRHB/BATRκA (SEQ ID NO: 21/SEQ ID NO: 15), BATRHB/BATRκB (SEQ ID NO: 21/SEQ ID NO: 16), BATRHC/BATRκB (SEQ ID NO: 22/SEQ ID NO: 16), BATRHB/BATRκD (SEQ ID NO: 21/SEQ ID NO: 18) и BATRHC/BATRκD (SEQ ID NO: 22/SEQ ID NO: 18), предпочтительно ...

СОЕДИНЕНИЯ НА ОСНОВЕ ПЛАТИНЫ И ЛИПИДОВ И НАНОЧАСТИЦЫ

СПОСОБЫ, КОМПОЗИЦИИ И ИЗДЕЛИЯ, СПОСОБСТВУЮЩИЕ ЛЕЧЕНИЮ РАКА

... 1. Способ, способствующий лечению рака, включающий введение агониста эндотелина B (ETB) и химиотерапевтического агента. ! 2. Способ по п.1, в котором указанный рак представляет собой солидную опухоль. ! 3. Способ по п.2, в котором указанную солидную опухоль выбирают из группы, состоящей из: опухоли яичников, опухоли толстой кишки, саркомы Капоши, опухоли молочной железы, меланомы, опухоли предстательной железы, менингиомы, опухоли печени, листовидной опухоли молочной железы и их комбинации. ! 4. Способ по п.1, в котором указанный агонист ETB выбирают из группы, состоящей из: ET-1, ET-2, ET-3, BQ3020, IRL1620 (N-suc-[Glu9,Ala11,15]ET-1(8-21)), сарафотоксина 56c, [Ala1,3,11,15]ET-1 и их комбинации. ! 5. Способ по п.1, в котором указанный химиотерапевтический агент выбирают из группы, состоящей из: адриамицина, камптотецина, карбоплатина, цисплатина, даунорубицина, доксорубицина, альфа-интерферона, бета-интерферона, гамма-интерферона, интерлейкина 2, иринотекана, доцетаксела, паклитаксела, ...

СПОСОБ ПОЛУЧЕНИЯ ПОЛИМЕРИЗОВАННЫХ КООРДИНАЦИОННЫХ СОЕДИНЕНИЙ КОМПЛЕКСА ПЛАТИНЫ

... 1. Способ получения координационного соединения в результате проведения реакции между комплексом платины и полимером, имеющим карбоксильные группы в своих боковых цепях, ! где в качестве комплекса платины используют комплекс диаквоплатина или комплекс бис(нитрато)платина в виде смеси с комплексом дигалогеноплатина, который выбирают из комплексов дихлоро-, дииодо- или дибромоплатина, а в качестве полимера используют блок-сополимер, описывающийся следующими общими формулами (1) или (2) ! ! где R1 представляет собой атом водорода или незамещенную или замещенную линейную или разветвленную С1-С12 алкильную группу, L1 и L2 независимо друг от друга представляют собой соединительные группы, R2 представляет собой метиленовую группу или этиленовую группу, R3 представляет собой атом водорода, защитную группу для аминогруппы, гидрофобную группу или полимеризуемую группу, R4 представляет собой гидроксильную группу, защищенную карбоксильную группу, образованную совместно с концевым -СО, или гидрофобную ...

Способ комбинированного лечения рака верхнеампулярного отдела прямой кишки

Изобретение относится к медицине, а именно к онкологии, и может быть использовано для комбинированного лечения рака верхнеампулярного отдела прямой кишки. Способ включает проведение курсов предоперационной химиотерапии по схеме оксалиплатин/лейковорин/5-фторурацил, проводят 3 курса химиотерапии. При этом оксалиплатин вводят в дозе 85 мг/мвнутривенно капельно в 1 день, длительность инфузии 2 часа, лейковорин в дозе 200 мг/мвнутривенно капельно в 1-2 дни, длительность инфузии 2 часа, 5-фторурацил в дозе 400 мг/мвнутривенно струйно в 1-2 дни, затем в дозе 600 мг/мвнутривенно капельно в 1-2 дни, длительность инфузии 22 часа, перерыв между курсами химиотерапии 3 недели. Использование изобретения позволяет улучшить результаты комбинированного лечения рака верхнеампулярного отдела прямой кишки за счет сокращения количества нежелательных явлений химиотерапии и снижения частоты послеоперационных осложнений. 1 пр.

Способ эндовитреального удаления парамакулярной меланомы хориоидеи грибовидной формы (Варианты)

Группа изобретений относится к области медицины, а именно к офтальмологии. Для лечения парамакулярной меланомы хориоидеи (MX) грибовидной формы проводят ее эндовитреальное удаление (эндорезекции) с минимальными анатомо-функциональными повреждениями сетчатки с помощью офтальмологической эндоскопической системы. По первому варианту способа при расстоянии от фовеа до края основания MX меньше 2 мм, субтотальную витрэктомию производят с использованием инструментов 25 G; существляют полную тампонаду ВП ПФОС с созданием повышенного внутриглазного давления (ВГД) до 50 мм рт.ст.; выполняют диатермокоагуляцию сетчатки и сосудистой оболочки вокруг видимых в операционный микроскоп границ M; проводят ретинотомию по границе диатермокоагуляции с последующей ретинэктомией полученной зоны над MX, при удалении части MX, обращенной к периферии глазного дна используют частоту резов витреотома 2000 резов/мин, а при удалении части MX ближе к заднему полюсу глаза - 5000 резов/мин, по всему периметру колобомы ...

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И/ИЛИ ЛЕЧЕНИЯ РАКОВЫХ ЗАБОЛЕВАНИЙ, ДЛЯ УВЕЛИЧЕНИЯ АКТИВНОСТИ ПРОТИВОРАКОВЫХ ЛЕКАРСТВ И СНИЖЕНИЯ ПОБОЧНЫХ ЭФФЕКТОВ ПРОТИВОРАКОВЫХ ЛЕКАРСТВ

... 1. Фармацевтическая композиция, отличающаяся тем, что она содержит наночастицы, обладающие высоким сродством к вырожденным клеткам, по меньшей мере, одно терапевтическое средство, выбираемое из группы, включающей актиномицин D, аминоглутетимид, антрациклины, амсакрин, анастрозол, анатагонисты пуриновых и пиримидиновых оснований, антрациклины, ингибиторы ароматазы, аспарагиназу, антиэстрогены, бексаротен, блеомицин, бузерелин, бусульфан, производные камптотецина, капецитабин, карбоплатин, кармустин, хлорамбуцил, цисплатин, кладрибин, циклофосфамид, цитарабин, цитозина арабинозид, алкилирующие цитостатики, дакарбазин, дактиномицин, даунорубицин, доцетаксел, доксорубицин (адриамицин), доксорубицин липо, эпирубицин, эстрамустин, этопозид, экземестан, флударабин, фторурацил, антагонисты фолиевой кислоты, форместан, гемцитабин, глюкокортикоиды, гозерелин, гормоны и гормональные антагонисты, гикамтин, гидроксимочевина, идарубицин, ифосфамид, иматиниб, иринотекан, милтефозин, митомицины, ингибиторы ...

НОВЫЕ КОМПОЗИЦИИ ЛИПОСОМ

... 1. Липосома направленного действия, включающая один или более фосфолипидов, производное N-(ω)-дикарбоновой кислоты и фосфатидилэтаноламина, модифицированное направляющим фактором производное N-(ω)-дикарбоновой кислоты и фосфатидилэтаноламина, инкапсулированное лекарственное вещество или меченое соединение и необязательно, по меньшей мере, один дополнительный липид, ! где модифицированное направляющим фактором производное N-(ω)-дикарбоновой кислоты и фосфатидилэтаноламина включает направляющий лиганд, присоединенный ко второму производному N-(ω)-дикарбоновой кислоты и фосфатидилэтаноламина; и ! где производное N-(ω)-дикарбоновой кислоты и фосфатидилэтаноламина представлено формулой 1, ! ; и ! второе производное N-(ω)-дикарбоновой кислоты и фосфатидилэтаноламина представлено формулой 3, ! , ! где R1, R2, R5 и R6, каждый независимо представляет собой ацильную группу, и m и p независимо представляют собой целое число от 1 до 10; и ! где липосома не включает немодифицированный фосфатидилэтаноламин ...

СПОСОБ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ МЕСТНО-РАСПРОСТРАНЕННЫХ ФОРМ РАКА ШЕЙКИ МАТКИ IIB-IIIB(T2b-T3bN0(1)M0) СТАДИЙ

СПОСОБ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ МЕСТНО-РАСПРОСТРАНЕННОГО РАКА ЖЕЛУДКА

ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ПРОТИВООПУХОЛЕВЫЙ КОМПЛЕКС ПЛАТИНЫ, И УСИЛИТЕЛЬ ПРОТИВООПУХОЛЕВОГО ЭФФЕКТА

ПРИМЕНЕНИЕ АНТАГОНИСТОВ CXCR2 ДЛЯ ПРЕДОТВРАЩЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ПЕРИФЕРИЧЕСКОЙ НЕВРОПАТИИ, ВЫЗВАННОЙ ХИМИОТЕРАПИЕЙ (CIPN)

Фармацевтическая композиция на основе соединения палладия

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ИНЪЕКЦИОННОГО, ОСОБЕННО ЦЕЛЕНАПРАВЛЕННОГО МЕСТНОГО ПРИМЕНЕНИЯ

... 1. Фармацевтическая композиция для инъекционного, в особенности, целенаправленного местного применения, характеризующаяся тем, что она включает стерильную суспензию комплекса (ОС-6-43)-бис(ацетато)-(1-адамантиламино)амин-дихлорплатины(IV) структурной формулы II ! (II) ! в фармацевтически приемлемой гидрофильной или гидрофобной инъекционной жидкой фазе, где 100% частиц платинового комплекса структурной формулы II имеют размер меньше, чем 250 мкм. ! 2. Фармацевтическая композиция по п.1, характеризующаяся тем, что 90% частиц комплекса структурной формулы II имеют размер меньше, чем 40 мкм, предпочтительно меньше, чем 10 мкм. ! 3. Фармацевтическая композиция по п.1, характеризующаяся тем, что массовое отношение комплекса структурной формулы II к жидкой фазе составляет от 1:100 до 30:100. ! 4. Фармацевтическая композиция по п.3, характеризующаяся тем, что массовое отношение комплекса структурной формулы II к жидкой фазе составляет от 5:100 до 10:100. ! 5. Фармацевтическая композиция по п.1, ...

НОВАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПО МЕНЬШЕЙ МЕРЕ ОДНО ПРОИЗВОДНОЕ ДОЛАСТАТИНА 10

... 1. Фармацевтическая композиция, включающая по меньшей мере одно соединение формулы (I) или его фармацевтически приемлемую соль в комбинации с капецитабином, трастузумабом, пертузумабом, иринотеканом или его фармацевтически приемлемой солью, или цисплатином, для одновременного, последовательного или раздельного введения при лечении рака, где R1 и R2 означают метил, этил, пропил, изопропил или бутил, R3 означает фенилалкил- или фенилдиалкиламино или фенилалкилокси, содержащий С1 -С4алкилен, где фенильная группа необязательно замещена одним, двумя или тремя заместителями, выбранными из группы, включающей галоген, алкоксикарбонил, сульфамоил, алкилкарбонилокси, карбамоилокси, циано, моно- или диалкиламино, алкил, алкокси, фенил, фенокси, трифторметил, трифторметокси, алкилтио, гидрокси, алкилкарбониламино, 1,3-диоксолил, 1,4-диоксолил, амино и бензил. 2. Фармацевтическая композиция, включающая по меньшей мере одно соединение формулы (I) или его фармацевтически приемлемую соль в комбинации с ...

ЛЕЧЕНИЕ ЛИМФОМ

КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ АНТИТЕЛ К КЛАУДИНУ 18.2 ДЛЯ ЛЕЧЕНИЯ РАКА

СПОСОБ ЛЕЧЕНИЯ РАКА АНТАГОНИСТОМ DLL4 И ХИМИОТЕРАПЕВТИЧЕСКИМ СРЕДСТВОМ

... 1. Выделенное антитело человека или его антигенсвязывающий фрагмент, которые специфически связывают дельта-подобный лиганд 4 человека (hDll4), для применения при лечении рака или замедлении или остановке роста опухоли у субъекта посредством введения в комбинации с химиотерапевтическим средством, где антитело человека или его антигенсвязывающий фрагмент содержит вариабельную область тяжелой цепи (HCVR), содержащую последовательности CDR1, CDR2 и CDR3 тяжелой цепи SEQ ID № 22, 24 и 26, соответственно, и вариабельную область легкой цепи (LCVR), содержащую последовательности легкой цепи CDR1, CDR2 и CDR3 SEQ ID № 30, 32 и 34, соответственно.2. Антитело человека или антигенсвязывающий фрагмент по п.1, где антитело или антигенсвязывающий фрагмент содержит последовательность HCVR SEQ ID № 20 или SEQ ID № 116 или последовательность LCVR SEQ ID № 28 или SEQ ID № 118.3. Антитело человека или антигенсвязывающий фрагмент по п.1, где указанное антитело или антигенсвязывающий фрагмент содержит комбинацию ...

СПОСОБЫ УВЕЛИЧЕНИЯ УРОВНЯ 2-ДЕЗОКСИУРИДИНА (DURD) В ПЛАЗМЕ И ИНГИБИРОВАНИЯ ТИМИДИЛАТСИНТАЗЫ

ГУМАНИЗИРОВАННЫЕ АНТИ-EGFL7-АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

... 1. Анти-EGFL7-антитело, включающее вариабельный домен, содержащий, по меньшей мере, одну, две, три, четыре или пять последовательностей гипервариабельного участка (HVR), выбранных из группы, состоящей из:(i) HVR-L1, содержащего KXSXSXDYXGDSYXS, где Xпредставляет А или R; Xпредставляет H или Q; Xпредставляет G или V; Xвыбран из группы, состоящей из D, L, R, S и W; и Xпредставляет M или V (SEQ ID NO:210);(ii) HVR-L2, содержащего GASXXEX, где Xпредставляет N или Y; Xвыбран из группы, состоящей из L, R и Y; и Xпредставляет Q или S (SEQ ID NO:211);(iii) HVR-L3, содержащего QQNNEXPXT, где Xпредставляет D или E; и Xпредставляет F или Y (SEQ ID NO:212);(iv) HVR-H1, содержащего GXXXXTYGXS, где Xпредставляет H или V; Xпредставляет R или T; Xвыбран из группы, состоящей из F, G, R и S; Xвыбран из группы, состоящей из D, G, R и T; и Xпредставляет M или Y (SEQ ID NO:213);(v) HVR-H2, содержащего GWINXXSGVPTXAXXXXX, где Xвыбран из группы, состоящей из I, M, T и W; Xпредставляет H или R; Xвыбран из группы ...

СПОСОБ УМЕНЬШЕНИЯ МУЛЬТИЛЕКАРСТВЕННОЙ РЕЗИСТЕНТНОСТИ С ИСПОЛЬЗОВАНИЕМ ТРИПИРОФОСФАТА ИНОЗИТА

... 1. Способ лечения рака, включающий введение субъекту, который в этом нуждается, терапевтически эффективного количества ITPP и введение указанному субъекту терапевтически эффективного количества химиотерапевтического агента после частичной сосудистой нормализации в опухоли.2. Способ по п. 1, дополнительно включающий выявление возникновения частичной сосудистой нормализации в опухоли.3. Способ по п. 2, где возникновение частичной сосудистой нормализации выявляют путем измерения уровня парциального давления кислорода (рО) в опухоли.4. Способ по п. 1, где химиотерапевтический агент вводят в субтерапевтической дозе.5. Способ по п. 4, где субтерапевтическая доза химиотерапевтического агента составляет менее 70% от утвержденной дозы.6. Фармацевтическая композиция, содержащая триспирофосфат инозита (ITPP) и химиотерапевтический агент, выбранный из паклитаксела и цисплатина.7. Фармацевтическая композиция по п. 6, где химиотерапевтический агент представляет собой паклитаксел.8. Фармацевтическая композиция ...

АНТИАНГИОГЕННАЯ ТЕРАПИЯ ДЛЯ ЛЕЧЕНИЯ РАКА ЯИЧНИКА

... 1. Способ лечения пациента, у которого диагностирован рак яичника, включающий воздействие на пациента режима лечения, комбинирующего химиотерапию с введением эффективного количества антитела против VEGF с последующей поддерживающей анти-VEGF терапией, где химиотерапия режима лечения включает введение по меньшей мере одного химиотерапевтического средства, и где режим лечения эффективно продлевает выживаемость пациента без прогрессирования.2. Способ по п.1, где химиотерапевтическое средство представляет собой таксан, паклитаксел, доцетаксел, частицы связанного с паклитакселом белка (например, Abraxane®), аналог платины, карбоплатин, гемцитабин или их комбинации.3. Способ по п.1, где химиотерапия режима лечения включает введение таксана и карбоплатина.4. Способ по п.1, где химиотерапия режима лечения включает введение карбоплатина и гемцитабина.5. Способ по п.1, где у пациента диагностирован ранее не подвергавшийся лечению рак яичника.6. Способ по п.1, где у пациента диагностирован рецидивирующий ...

СОЕДИНЕНИЯ НА ОСНОВЕ ПЛАТИНЫ И ЛИПИДОВ И НАНОЧАСТИЦЫ

КОМБИНАЦИИ ТЕРАПЕВТИЧЕСКИХ АГЕНТОВ ДЛЯ ЛЕЧЕНИЯ РАКА

... 1. Способ предупреждения или лечения пролиферативного заболевания, предусматривающий введение фармацевтически эффективных количеств комбинации: (а) 7-трет-бутоксииминометилкамптотецина и (б) одного или нескольких химиотерапевтических агентов, выбранных из паклитаксела, доцетаксела, эпотилона В, темозоламида, 5-ФУ (5-фторурацила), гемцитабина, оксалиплатина, цисплатина, карбоплатина, доксорубицина, {6-[4-(4-этил-пиперазин-1-илметил)-фенил]-7Н-пирроло[2,3-d]пиримидин-4-ил]-((R)-1-фенил-этил)-амина, эверолимуса, иматиниба, эрлотиниба, бевацизумаба, цетуксимаба и велкада, для одновременного, согласованного, раздельного или последовательного применения для предупреждения или лечения пролиферативного заболевания. 2. Фармацевтическая композиция, включающая: (а) 7-трет-бутоксииминометилкамптотецин и (б) один или несколько химиотерапевтических агентов, выбранных из паклитаксела, доцетаксела, эпотилона В, темозоламида, 5-ФУ, гемцитабина, оксалиплатина, цисплатина, карбоплатина, доксоубицина, {6-[ ...

КОМБИНИРОВАННАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ОПУХОЛЕЙ

... 1. Применение воды с пониженным содержанием дейтерия (DDW) для приготовления комбинированной фармацевтической композиции для профилактики или лечения опухолевых заболеваний, причем композиция включает DDW с содержанием дейтерия (D) в диапазоне от 0,01 до 135 м.д. и один или несколько противоопухолевых агентов, необязательно совместно с одним или несколькими стандартными вспомогательными фармацевтическими материалами.2. Применение по п. 1, отличающееся тем, что форма комбинированной композиции выбрана из следующих: раствор для инфузии, раствор для инъекций, раствор для внутрибрюшинного введения, раствор для орошения, раствор для ингаляции или раствор для клизм.3. Применение по п. 1 или 2, отличающееся тем, что противоопухолевый агент выбран из следующих: ингибиторы тирозинкиназы, алкилирующие агенты, антиметаболиты, алкалоиды лекарственных трав, цитотоксические антибиотики, моноклональные антитела, антиандрогены, соединения платины, ингибиторы топоизомеразы, метилгидразиды.4. Применение ...

КОМБИНАЦИИ СОЕДИНЕНИЙ, ИНГИБИРУЮЩИХ АКТ, И ХИМИОТЕРАПЕВТИЧЕСКИХ АГЕНТОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

... 1. Комбинация а) соединения формулы I:или его фармацевтически приемлемой соли; и b) одного или нескольких средств, выбранных из 5-FU, платинового агента, лейковорина, иринотекана, доцетаксела, доксорубицина, гемцитабина, SN-38, капецитабина, темозоломида, паклитаксела, бевацизумаба, пертузумаба, тамоксифена, рапамицина и лапатиниба, или его фармацевтически приемлемой соли для профилактики или терапевтического лечения гиперпролиферативного нарушения.2. Комбинация по п.1, где гиперпролиферативным нарушением является злокачественное новообразование.3. Комбинация по п.2, где злокачественное новообразование связано с мутацией PTEN.4. Комбинация по п.2, где злокачественное новообразование связано с мутацией AKT, сверхэкспрессией или амплификацией.5. Комбинация по п.2, где злокачественное новообразование связано с мутацией PI3K.6. Комбинация по п.2, где злокачественное новообразование связано с мутацией или амплификацией Her2/ErbB2.7. Комбинация по п.1, где комбинация обеспечивает синергетический ...

КОМБИНАЦИИ СОЕДИНЕНИЙ-ИНГИБИТОРОВ АКТ И АБИРАТЕРОНА И СПОСОБЫ ПРИМЕНЕНИЯ

... 1. Комбинация a) соединения формулы Ia:или его фармацевтически приемлемой соли и b) абиратерона или его фармацевтически приемлемой соли для профилактического или терапевтического лечения гиперпролиферативного нарушения.2. Комбинация по п.1, где гиперпролиферативным нарушением является рак.3. Комбинация по п.2, где рак ассоциирован с мутацией PTEN.4. Комбинация по п.2, где рак ассоциирован с мутацией, оверэкспрессией или амплификацией AKT.5. Комбинация по п.2, где рак ассоциирован с мутацией PI3K.6. Комбинация по п.2, где рак ассоциирован с мутацией Her2/ErbB2.7. Комбинация по любому из пп.2-6, где рак выбран из рака молочной железы, легкого, яичников, предстательной железы, меланомы, рака желудка, толстой кишки, почки, головы и шеи, и глиомы.8. Комбинация по любому из пп.1-6, где комбинация обеспечивает синергический эффект при лечении гиперпролиферативного нарушения.9. Комбинация по п.8, где значение комбинаторного индекса синергического эффекта составляет менее чем приблизительно 0,8.10 ...

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОМПЛЕКС ПЛАТИНЫ В КАЧЕСТВЕ АКТИВНОГО ВЕЩЕСТВА, И СПОСОБ ЕЕПОЛУЧЕНИЯ

... 1. Фармацевтическая композиция, содержащая комплекс платины формулы (I) в качестве активного вещества где А и A' независимо друг от друга представляют собой группу NH3 или аминогруппу или диаминогруппу, содержащую от 1 до 18 атомов углерода; В и В' независимо друг от друга представляют собой атом галогена, гидроксильную группу или группу COOR или COOR', где R и R' независимо друг от друга представляют собой атом водорода или алкильную, алкенильную, арильную, аралкильную, алкиламиновую или алкоксильную группу, содержащую от 1 до 10 атомов углерода, или функциональные производные указанных групп; и Х и Х' независимо друг от друга представляют собой атом галогена или монокарбоксилатную группу, содержащую от 1 до 20 атомов углерода, или Х и Х' вместе образуют дикарбоксилатную группу, содержащую от 2 до 20 атомов углерода, в смеси с по меньшей мере одним фармацевтически приемлемым эксципиентом, отличающаяся тем, что она образована из гранулята с размером частиц менее 0,5 мм, полученного влажным ...

AXL-АНТИТЕЛА

... 1. Моноклональное антитело, которое связывается с внеклеточным доменом AXL и, по меньшей мере, частично ингибирует AXL-активность. ! 2. Моноклональное антитело по п.1, которое снижает и/или блокирует AXL-опосредованную сигнальную трансдукцию, снижает и/или блокирует AXL-фосфорилирование, снижает и/или блокирует клеточную пролиферацию, снижает и/или блокирует ангиогенез, снижает и/или блокирует миграцию клеток, снижает и/или блокирует метастазирование опухоли, снижает и/или блокирует AXL-опосредованный анти-апоптоз, снижает и/или блокирует AXL-опосредованную PI3К-передачу сигналов. ! 3. Моноклональное антитело по п.1, которое является рекомбинантным антителом, гуманизированным антителом, химерным антителом, мультиспецифичным антителом или его фрагментом. ! 4. Моноклональное антитело по п.1, которое является химерным антителом и содержит аминокислотную последовательность тяжелой цепи, выбранную из группы, состоящей из SEQ ID NO: 38, 39, 41, 42, или, по меньшей мере, ее вариабельный домен ...

New therapeutic use

Functionalised silicon nanoparticles

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) activity

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) activity8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3-(7H)-one compounds of formula (I) or isomers, stereoisomers, enantiomers, salts, solvates, chemically protected forms or pro-drugs thereof, wherein Y and Z are each independently selected from an optionally substituted aryl, heteroaryl or substitutent; R1, R2and R3are each independently selected from hydrogen, halogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, cycloalkyl, alkynyl, cyano, haloalkoxy, haloalkyl, hydroxyl, hydroxyalkylene, nitro, NRARB, (NRARB)alkylene and (NRARB)carbonyl, wherein RAand RBare independently selected from hydrogen alkyl, cycloalkyl and alkylcarbonyl or together with the atom to which they are attached form a 3-10 membered heterocyclic ring optionally having one to three heteroatoms or heterofunctionalities; A and B are each independently selected from hydrogen, Br, Cl, F, I, OH, or an optionally substituted C1-C6alkyl, C3-C8cycloalkyl, ...

Polymorphic form (I) of platinum (IV) complex

Cancer

Substituted imidazopyridazines

Combination therapy for ovarian cancer

Substituted imidazopyridazines

Anti-IGF antibodies

METHOD FOR ISOLATING A CHEMOTHERAPEUTIC AGENT RESISTANT CANCER CELL WITH STEM CELL PROPERTIES

Combination therapy for ovarian cancer

Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent

A combination of pharmaceutical preparations, which are simultaneously, separately, or successively administered in treatments for cancers. It comprises the following two separate preparations: * a pharmaceutical preparation comprising a pharmaceutically acceptable support or diluent and either at least one compound represented by the general formula [I]: [I] (wherein R1 and R2 each independently represents hydrogen, (I) lower alkyl, etc.; G represents a pentose group, etc.; and X1 and X2 each independently represents hydrogen, halogeno, etc.) or a pharmaceutically acceptable salt of the compound and * a pharmaceutical preparation comprising a pharmaceutically acceptable support or diluent and any of an anticancer alkylating agent, anticancer antimetabilite, anticancer antibiotic, plant-derived anticancer agent, and the like (the pharmaceutical preparation containing at least one compound represented by the above formula [I] or a pharmaceutically acceptable salt thereof may be used in combination ...

Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties

Combination therapy for hyperproliferative diseases.

Combination therapy for ovarian cancer

Anti-IGF antibodies.

Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent.

Combination therapy for hyperproliferative diseases.

Combination therapy for hyperproliferative diseases.

Combination therapy for ovarian cancer

Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties

Substituted imidazopyridazines

Anti-IGF antibodies.

Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent

Anti-IGF antibodies.

Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties

Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent

OXALIPLATIN ANTIRESISTENZVERFAHREN

PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION

ANTIPROLIFERATIVE COMBINATION THERAPY WITH SATRAPLATIN OR JM118 AND DOCETAXEL

THERAPY PROCEDURE

PYRROLOÄ2,3-DÜPYRIMIDINE FOR THE TREATMENT OF CANCER BY MITOTIC INHIBITION

Method of reducing multi-drug resistance using inositol tripyrophosphate

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Chroman derivatives, medicaments and use in therapy

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

Pentamidine combinations for treating cancer

The present invention relates to the treatment of cancer, e.g., ovarian cancer, breast cancer, pancreatic cancer or colon cancer, with pentamidine and (a) oxaliplatin, (b) gemcitabine, (c) taxol, (d) 5-fluorouracil or (e) CPT 11.

process for preparing trichloroammineplatinate salt and the products obtained therein

The present invention relates to a process for preparing a trichloroammineplatinate salt by reacting a tetrachloroplatinate salt in aqueous solution in the presence of ammonium chloride and an alkali chloride with one or more carbonate salts selected from the group consisting of potassium, sodium and ammonium carbonate while keeping the pH value below 7 during the reaction; the product obtained therein and a use thereof.

Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor

The combination of a biocompatible electron donor and a platinum-based antineoplastic agent exhibits improved efficacy in treating cancer This improved activity appears to be the result of electron transfer from the aforementioned donor compound to the platinum-based antineoplastic agent As the electron donor alone has no chemotherapeutic utility in treating cancer, the resulting combinations appear to be synergistic in nature In select preferred embodiments, the biocompatible electron donor is an amine (such as N,N,N′,N′-tetramethyl-p-phenylene diamine or indocyanine green), a phenolic compound (such as a flavanol or catechin), or a quinone (such as an aromatic quinone), while the antineoplastic is cisplatin.

Chroman derivatives, medicaments and use in therapy

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

Treatment of lung cancer

Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.

Local treatment of neurofibromas

A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.

Paraben compositions

The present invention provides paraben compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration.

Anti-cancer agent delivery vehicles capable of improved loading

There is provided a conjugate of a delivery agent containing a chemical moiety and at least one flavonoid. The flavonoid exists in a monomeric form or dimeric form before conjugation and remains in the monomeric form or dimeric form after conjugation. Preferably, the conjugate comprises two flavonoids. The delivery agent is conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. An anti-cancer agent delivery vehicle comprising an anti-cancer agent and the conjugate is also provided.

COMBINATORIAL THERAPIES FOR THE TREATMENT OF NEOPLASIAS USING THE OPIOID GROWTH FACTOR RECEPTOR

The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor. 1. A pharmaceutical composition for treating neoplasias in an animal or human which are characterized by an opioid growth factor receptor , comprising:therapeutically effective amounts of at least one chemotherapeutic, biotherapeutic, and/or radionuclide agent with between about 20 to 1000 μg/kg body weight of an opioid growth factor; and a carrier.2. The pharmaceutical composition of wherein said agent is a therapeutic agent.3. The pharmaceutical composition of claim 2 , wherein the neoplasias includes not limited to pancreatic cancer claim 2 , squamous cell cancer of the head and neck claim 2 , breast cancer claim 2 , colorectal cancer claim 2 , renal cancer claim 2 , brain cancer claim 2 , prostate cancer claim 2 , bladder cancer claim 2 , bone or joint cancer claim 2 , uterine cancer claim 2 , cervical cancer claim 2 , endometrial cancer claim 2 , multiple myeloma claim 2 , Hodgkin's disease claim 2 , non-Hodgkin's lymphoma claim 2 , melanoma claim 2 , leukemias claim 2 , lung cancer claim 2 , ovarian cancer claim 2 , gastrointestinal cancer claim 2 , Kaposi's sarcoma claim 2 , liver cancer claim 2 , pharyngeal cancer and laryngeal cancer.4. The pharmaceutical composition of claim 3 , wherein the chemotherapeutic agent is selected from but not limited to the ...

CHOLESTANOL DERIVATIVE FOR COMBINED USE

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): 2. A cancer chemotherapeutic agent according to claim 1 , wherein claim 1 , in formula (1) claim 1 , G is GlcNAc-Gal- or GlcNAc-.3. A cancer chemotherapeutic agent according to or claim 1 , wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent claim 1 , a platinum complex anti-cancer agent claim 1 , a pemetrexed compound claim 1 , and fluorouracil.4. A cancer chemotherapeutic agent according to claim 3 , wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel claim 3 , Docetaxcel claim 3 , Pemetrexed claim 3 , 5-FU claim 3 , Cisplatin claim 3 , Oxaliplatin claim 3 , Cyclophosphamide claim 3 , and Irinotecan.5. A cancer chemotherapeutic agent according to any of to claim 3 , which is a compounding agent.6. A cancer chemotherapeutic agent according to any of to claim 3 , which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent.7. A cancer chemotherapeutic agent according to claim 6 , wherein the drug containing a cholestanol derivative is a liposomal formulation.10. A cancer chemotherapy according to claim 9 , wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously claim 9 , or separately and intermittently. 1. Field of the InventionThe present invention relates to a chemotherapeutic agent for cancer (hereinafter referred to as a “cancer chemotherapeutic agent”) and, more particularly, to a cancer chemotherapeutic agent employing a cholestanol derivative and an anti-cancer agent in combination.2. Background ArtA variety of anti-cancer agents used in chemotherapy for ...

Combinational Liposome Compositions for Cancer Therapy

The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome. 1. A method for delivering a therapeutic agent to a subject , the method comprising:a) administering to the subject a liposome comprising a therapeutic agent; andadministering to the subject a lipid nanoparticle comprising a non-ionic triggering agent;whereby release of the therapeutic agent from the liposome following administration of the lipid nanoparticle is increased, relative to the release of the therapeutic agent from the liposome without administration of the lipid nanoparticle.2. The method of claim 1 , wherein the liposome comprises one or more lipids selected from the group consisting of a phospholipid claim 1 , a steroid claim 1 , and a cationic lipid.3. The method of claim 2 , wherein the phospholipid is selected from a phophatidylcholine claim 2 , a phosphatidylglycerol claim 2 , a phosphatidylethanolamine claim 2 , a phosphatidylserine claim 2 , a phosphatidylinositol claim 2 , and a phosphatidic acid.4. The method of claim 3 , wherein the phosphatidylcholine is DSPC.5. The method of claim 3 , wherein the phosphatidylglycerol is DSPG.6. The method of claim 3 , wherein the phosphatidylethanolamine is DSPE-PEG(2000).7. The method of claim 2 , wherein the steroid is cholesterol.8. The method of claim 1 , wherein the lipid nanoparticle is selected from the group consisting of a second liposome claim 1 , a micelle claim 1 , and mixtures thereof.9. The method of claim 8 , wherein the lipid nanoparticle is a second liposome.10. The method of claim 9 , wherein the second liposome comprises one or more lipids selected from the group consisting of a phospholipid claim 9 , a steroid claim 9 , and a cationic lipid.11. The method of ...

Compounds Useful as Inhibitors of ATR Kinase

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 4. The compound of claim 1 , wherein Ring B is phenyl claim 1 , thienyl claim 1 , or morpholinyl.50. The compound of claim claim 1 , wherein Ring B is phenyl or thienyl.6. The compound of claim 5 , wherein m is 0 and n is 1.70. The compound of claim claim 5 , wherein{'sub': 1-6', '1-6, 'X is Calkyl wherein 0-2 methylene units of said Calkyl are replaced with NH or O;'}{'sub': 1-4', '1-3, 'Y is hydrogen, Calkyl, or a 3-7 membered saturated or partially unsaturated heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the heterocyclyl is optionally substituted with 1 occurrence of halo or Calkyl;'}q is 0 or 1.80. The compound of claim claim 5 , wherein Jis —Calkyl claim 5 , —OH claim 5 , —OCH claim 5 , —CHNHCH claim 5 , —CHOH claim 5 , —OCHCHOH claim 5 , —CHNH-(morpholinyl) claim 5 , or morpholinyl.9. The compound of claim 5 , wherein m is 1 and n is 0.100. The compound of claim claim 5 , wherein J is halo.12. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.13. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.140. The method of claim claim 1 , further comprising administering to said ...

Compounds Useful as Inhibitors of ATR Kinase

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 43. The compound of any one of - claims 1 , wherein Q is phenyl.5. The compound of claim 4 , wherein p is 0; q is 1; and Jis a Caliphatic group wherein one methylene unit is replaced with S(O).6. The compound of claim 5 , wherein Jis SOCH(CH).7. The compound of wherein Ring B is phenyl.8. The compound of claim 1 , wherein n and m are both 0.10. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.11. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.12. The method of claim 11 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.1328-. (canceled)29. The method of claim 11 , wherein said cancer is selected from non-small cell lung cancer claim 11 , small cell lung cancer claim 11 , pancreatic cancer claim 11 , biliary tract cancer claim 11 , head and neck cancer claim 11 , bladder cancer claim 11 , colorectal cancer claim 11 , ...

Compounds Useful as Inhibitors of ATR Kinase

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

TRIAZOLOPYRIDINE DERIVATIVES

The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds. 5. The compound according to which is selected from the group consisting of:4-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxybenzonitrile;4-{2-[(2,4-dimethoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;4-{2-[(2-methoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;2,6-dimethyl-4-[2-(pyrimidin-5-ylamino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenol;4-{2-[(2,5-dimethoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;4-{2-[(5-fluoro-2-methoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;2-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}benzonitrile;2,6-dimethyl-4-[2-(pyridin-3-ylamino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenol;2,6-dimethyl-4-(2-{[4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenol;2,6-dimethyl-4-(2-{[2-(trifluoromethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenol;4-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}benzonitrile;4-{2-[(2-ethoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;3-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-4-methoxybenzonitrile;4-{2-[(3-methoxypyridin-2-yl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,6-dimethylphenol;4-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-N-methylbenzamide;N,N-Diethyl-4-[6-( ...

METHOD FOR TREATMENT OF ADVANCED SOLID TUMORS

The present invention relates to the use of Volasertib or a salt thereof or a hydrate thereof in combination with Cisplatin or Carboplatin or a salt thereof or a hydrate thereof for treating patients suffering from advanced and/or metastatic solid tumours. 1. A method of treating advanced and/or metastatic solid tumours , comprising administering 300 to 500 mg Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof to a patient at one day during a 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 or 31 day treatment cycle.2. A method of treating advanced and/or metastatic solid tumours , comprising administering a dosage schedule (I) comprising or consisting ofa) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and{'sup': '2', 'b) 50 to 100 mg/mBSA of Cisplatin at one day within the same treatment cycle,'}to a patient suffering from advanced and/or metastatic solid tumours.3. A method of treating advanced and/or metastatic solid tumours , comprising administering a dosage schedule (I) comprising or consisting ofa) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle andb) Carboplatin at a dose targeting AUC=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle,to a patient suffering from advanced and/or metastatic solid tumours.4. The method according to or , wherein the treatment cycle is 14 , 21 or 28 days.5. The method according to claim 2 , wherein Volasertib and Cisplatin are administered at the same day.6. The method according to claim 3 , wherein Volasertib and Carboplatin are administered at the same day.7. The method according to claim 5 , wherein Volasertib and Cisplatin are ...

METHOD FOR PREPARING NOVEL PROCESSED GINSENG OR AN EXTRACT THEREOF, THE USUALLY MINUTE GINSENOSIDE CONTENT OF WHICH IS INCREASED

The present invention relates to a method for preparing a processed ginseng or processed ginseng extract. Specifically, the invention relates to a method for preparing a processed ginseng or processed ginseng extract having increased ginsenoside contents. More specifically, the invention relates to a method of preparing a novel processed ginseng or processed ginseng extract having increased ginsenoside contents by preparing saponinase, fermenting ginseng or red ginseng with the prepared saponinase and hydrolyzing the fermented ginseng or red ginseng with an organic acid and to an anticancer supplement composition or pharmaceutical composition comprising the processed ginseng or processed ginseng extract prepared thereby. 1. A method for preparing a processed ginseng or processed ginseng extract having increased contents of ginsenosides Rg3 and Rh2 , the method comprising the steps of:{'i': 'Aspergillus niger', '(a) inoculating an strain into a medium composed of ginseng and wheat bran;'}(b) culturing the strain of step (a);(c) purifying the cultured material of step (b) by ultrafiltration;(d) separating an enzyme from the purified material of step (c);(e) adding the enzyme of step (d) to ginseng, red ginseng or a ginseng or red ginseng extract to obtain a mixture;(f) fermenting the mixture of step (e);(g) separating the fermented material of step (f) to obtain a supernatant;(h) concentrating the supernatant of step (g);(i) reacting the concentrate of step (h) with at least one organic acid selected from the group consisting of acetic acid, lactic acid, citric acid, malic acid and tartaric acid; and(j) neutralizing, filtering, purifying, concentrating and drying the reaction product of step (i).2Aspergillus nigerAspergillus niger. The method of claim 1 , wherein inoculation of the medium with in step (a) is performed such that the number of spores in an spore suspension is 5×10spores per g of the medium and the initial water content of the medium is maintained at 50- ...

Humanized anti-egfl7 antibodies and methods using same

The present invention concerns antibodies to EGFL7 and the uses of same.

HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME

The present invention concerns antibodies to EGFL7 and the uses of same. 1. A method of enhancing efficacy of an anti-angiogenesis agent in a subject having a pathological condition associated with angiogenesis , the method comprising administering to an individual in need of such treatment an effective amount of an anti-EGFL7 antibody , the antibody comprising the following hypervariable region (HVR) sequences:{'sub': 1', '2', '3', '4', '5', '1', '2', '3', '4', '5, '(i) HVR-L1 comprising KXSXSXDYXGDSYXS, wherein Xis A or R; Xis H or Q; Xis G or V; Xis selected from the group consisting of D, L, R, S, and W; and Xis M or V (SEQ ID NO: 210);'}{'sub': 1', '2', '3', '1', '2', '3, '(ii) HVR-L2 comprising GASXXEX, wherein Xis N or Y; Xis selected from the group consisting of L, R and Y; and Xis Q or S (SEQ ID NO: 211);'}{'sub': 1', '2', '1', '2, '(iii) HVR-L3 comprising QQNNEXPXT, wherein Xis D or E; and Xis F or Y (SEQ ID NO: 212);'}{'sub': 1', '2', '3', '4', '5', '1', '2', '3', '4', '5, '(iv) HVR-H1 comprising GXXXXTYGXS, wherein Xis H or V; Xis R or T; Xis selected from the group consisting of F, G, R, and S; Xis selected from the group consisting of D, G, R, and T; and Xis M or Y (SEQ ID NO: 213);'}{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '1', '2', '3', '4', '5', '6', '7', '8, '(v) HVR-H2 comprising GWINXXSGVPTXAXXXXX, wherein Xis selected from the group consisting of I, M, T, and W; Xis H or R; Xis selected from group consisting of I, M, T, and Y; Xis D or H; Xis selected from group consisting of D, M and T; Xis F or Y; Xis K or S; and Xis G or R (SEQ ID NO: 214, and'}{'sub': 1', '2', '3', '1', '2', '3, '(vi) HVR-H3 comprising AXLGSXAVDX, wherein Xis N or R; Xis selected from the group consisting of C, R, H, and Y; and Xis A or Y (SEQ ID NO: 215).'}2. A method of enhancing efficacy of an anti-angiogenesis agent in a subject having a pathological condition associated with angiogenesis , the method comprising administering to an individual in need of such ...

NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II

Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor. 1. Humanized 12G4 monoclonal antibody comprising or consisting of: a variable region the amino acid sequence of which is represented by SEQ ID NO: 2 or SEQ ID NO: 4, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 6 or by a sequence having at least 80% homology with SEQ ID NO: 6,, 'a) a light chain comprising or consisting of a variable region the amino acid sequence of which is represented by SEQ ID NO: 8, or SEQ ID NO: 10, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 12 or by a sequence having at least 80% homology with SEQ ID NO: 12,, 'b) a heavy chain comprising or consisting of{'sub': 'D', 'claim-text': a variable region the amino acid sequence of which is represented by SEQ ID NO: 14, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 6,, 'said humanized 12G4 monoclonal antibody is mutated, comprises at least one mutation in the light and/or heavy chain, and has a Kfor the human anti-Müllerian hormone type II receptor (AMHRII) at least equal to that of the chimeric 12G4 monoclonal antibody comprising or consisting of a variable region the amino acid sequence of which is represented by SEQ ID NO: 18, or SEQ ID NO: 10, and', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 12,, 'b) a heavy chain consisting of{'sup': −9', '−8', '−9', '−11, 'for said receptor, preferably below 10M, in particular below 10M, in particular in the range from 10M to 10M.'}2. Mutated humanized 12G4 monoclonal antibody according to claim 1 , comprising at least one mutation in at least one CDR of the variable region of the light chain claim 1 , and having an affinity for said receptor at least equal to that of said chimeric 12G4 monoclonal antibody.3. Mutated humanized 12G4 monoclonal antibody according to claim 1 , ...

Crystal Forms of Kinase Inhibitors

N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer. 122-. (canceled)24. The method of claim 23 , wherein the solution is administered by a parenteral route.25. The method of claim 23 , further comprising administering 5-azacitidine claim 23 , docetaxel claim 23 , cisplatin claim 23 , or carboplatin.27. The method of claim 26 , wherein the solution is administered by a parenteral route.28. The method of claim 26 , further comprising administering 5-azacitidine claim 26 , docetaxel claim 26 , cisplatin claim 26 , or carboplatin.30. The method of claim 29 , wherein the solid dispersion is administered by an oral route.31. The method of claim 29 , further comprising administering 5-azacitidine claim 29 , docetaxel claim 29 , cisplatin claim 29 , or carboplatin.33. The method of claim 32 , wherein the solid dispersion is administered by an oral route.34. The method of claim 32 , further comprising administering 5-azacitidine claim 32 , docetaxel claim 32 , cisplatin claim 32 , or carboplatin. This application claims priority to U.S. Provisional Application Ser. No. 61/353,058 filed Jun. 9, 2010, which is incorporated by reference in its entirety.The present invention relates to crystalline forms of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, processes for preparing the crystalline forms, pharmaceutical formulations thereof, and methods of treating cancer.Mitosis is a process by which a complete copy of a duplicated genome is segregated by the microtuble spindle apparatus into two daughter cells. Aurora-kinases, key mitotic regulators required for genome stability, have been found to be overexpressed in human tumors. There is therefore an existing need in the therapeutic arts for ...

Cancer Treatment Method

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. 1(i) a compound of formula (I″). A method of treating gastric cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of(ii) oxaliplatin, and(iii) capecitabine. This application is filed as a continuation application of U.S. application Ser. No. 13/209,889 filed Aug. 15, 2011, and U.S. application Ser. No. 12/516,661 filed May 28, 2009, now abandoned, which is a National Phase Application of International Application No. PCT/US2007/84215 filed Nov. 9, 2007, which claims priority from U.S. Provisional Application Nos. 60/867,431 filed Nov. 28, 2006; 60/943,662 filed Jun. 13, 2007; and 60/951,271 filed Jul. 23, 2007.The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines in combination with other anti-neoplastic compounds. In particular, the method relates to methods of treating cancers by administration of a combination of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine or salts or solvates thereof along with additional anti-neoplastic compounds.Effective chemotherapy for cancer treatment is a continuing goal in the oncology field. Generally, cancer results from the deregulation of the normal processes that control cell division, differentiation and apoptotic cell death. Apoptosis (programmed cell death) plays essential roles in embryonic development and pathogenesis of various diseases, such as degenerative neuronal diseases, ...

Substituted Triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds. 2. The compound according to claim 1 , wherein:{'sup': '1', 'claim-text': 'which is substituted, one or more times, identically or differently, with a substituent selected from:', 'Rrepresents an aryl or heteroaryl group'}{'sup': 6', '6', '6', '6', '6', '6', '6', '6', '6', '6', '7', '6', '6', '7', '7', '6', '7', '6', '7', '6', '6', '7', '6', '6', '6', '6', '7', '6', '6', '6', '7', '6', '7', '6', '6', '6', '7', '6', '7', '7', '6', '6', '7, 'sub': 2', 'n', '2', 'm', '1', '6', '2', 'n', '2', 'p', '1', '6', '1', '6', '1', '6', '1', '6', '2', '2', '2', '2', '2, 'claim-text': and', {'sup': 'xy', 'which is optionally substituted, one or more times, identically or differently, with a substituent Rselected from, {'sub': 1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'sup': 8', '7', '8', '8', '8', '7, 'halo-, hydroxyl-, cyano-, C-C-alkyl-, halo-C-C-alkyl-, C-C-alkoxy-, halo-C-C-alkoxy-, hydroxy-C-C-alkyl-, —N(H)C(═O)R, —N(R)C(═O)R, —C(═O)N(H)R, —C(═O)NRR;'}], 'R—(CH)(CHOH)(CH)—, R—(C-C-alkoxy)-, R—(CH)(CHOH)(CH)—O—, R—(C-C-alkoxy-C-C-alkyl)-, R—(C-C-alkoxy-C-C-alkyl)-O—, R—O—, —C(═O)R, —C(═O)O—R, —OC(═O)—R, —N(H)C(═O)R, —N(R)C(═O)R, —N(H)C(═O)NRR, —N(R)C(═O)NRR, —NRR, —C(═O)N(H)R, —C(═O)NRR, R—S—, R—S(═O)—, R—S(═O)—, —N(H)S(═O)R, —N(R)S(═O)R, —S(═O)N(H)R, —S(═O)NRR, —N(H)S(═O)R, —N(R)S(═O)R, —S(═O)N(H)R, —S(═O)NRR, —S(═O)(═NR)R, —S(═O)(═NR)R, —N═S(═O)(R)R;'}or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a ...

TREATMENT WITH ANTI-VEGF ANTIBODIES

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. 1. A method of treating cancer in a human patient , comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-neoplastic composition , wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent.2. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer claim 1 , colorectal cancer claim 1 , rectal cancer claim 1 , non-small cell lung cancer claim 1 , non-Hodgkins lymphoma (NHL) claim 1 , renal cell cancer claim 1 , prostate cancer claim 1 , liver cancer claim 1 , pancreatic cancer claim 1 , soft-tissue sarcoma claim 1 , kaposi's sarcoma claim 1 , carcinoid carcinoma claim 1 , head and neck cancer claim 1 , melanoma claim 1 , ovarian cancer claim 1 , mesothelioma claim 1 , and multiple myeloma.3. The method of claim 1 , wherein the cancer is metastatic.4. The method of claim 1 , wherein the patient is previously untreated.5. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents claim 1 , antimetabolites claim 1 , folic acid analogs claim 1 , pyrimidine analogs claim 1 , purine analogs and related inhibitors claim 1 , vinca alkaloids claim 1 , epipodopyyllotoxins claim 1 , antibiotics claim 1 , L-Asparaginase claim 1 , topoisomerase inhibitor claim 1 , interferons claim 1 , platinum coordination complexes claim 1 , anthracenedione substituted urea claim 1 , methyl hydrazine derivatives claim 1 , adrenocortical suppressant claim 1 , adrenocorticosteroides claim 1 , progestins claim 1 , estrogens claim 1 , antiestrogen claim 1 , androgens claim 1 , antiandrogen claim 1 ...

COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. 1. A composition comprising: (a) nanoparticles comprising paclitaxel and albumin and (b) an anti-VEGF antibody.2. The composition of claim 1 , wherein the anti-VEGF antibody is bevacizumab.3. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is between about 0.01:1 and about 100:1.4. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is less than about 30:1.5. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is less than about 10:1.6. The composition of claim 2 , wherein the weight ratio of the paclitaxel and the bevacizumab is less than about 10:1.7. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is about 2:1 to about 3:1.8. The composition of claim 2 , wherein the weight ratio of the paclitaxel and the bevacizumab is about 2:1 to about 3:1.9. The composition of claim 1 , wherein the composition further comprises a platinum-based agent.10. The composition of claim 9 , wherein the platinum-based agent is carboplatin.11. The composition of claim 1 , wherein the nanoparticles comprise paclitaxel coated with albumin.12. The composition of claim 8 , wherein the nanoparticles comprise paclitaxel coated with albumin.13. The composition of claim 1 , wherein the average diameter of the nanoparticles in the composition is no greater ...

Methods and compositions for malic enzyme 2 (me2) as a target for cancer therapy

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.

ANTI-IGF ANTIBODIES

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer. 118-. (canceled)19) A DNA molecule encoding the variable heavy chain or the variable light chain of an antibody molecule , which i) binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and', 'ii) IGF-1 receptor-mediated signaling is inhibited,, 'a) binds to human IGF-1 and IGF-2 such that'}b) binds to mouse and rat IGF-1 and IGF-2,c) does not bind to human insulin; i) an antibody molecule that has heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and that has light chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3);', 'ii) an antibody molecule that has heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:11 (CDR1), SEQ ID NO:12 (CDR2) and SEQ ID NO:13 (CDR3) and that has light chain CDRs comprising the amino acid sequences of SEQ ID NO:14 (CDR1), SEQ ID NO:15 (CDR2) and SEQ ID NO:16 (CDR3);', 'iii) an antibody molecule that has heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:21 (CDR1), SEQ ID NO:22 (CDR2) and SEQ ID NO:23 (CDR3) and that has light chain CDRs comprising the amino acid sequences of SEQ ID NO:24 (CDR1), SEQ ID NO:25 (CDR2) and SEQ ID NO:26 (CDR3),, 'wherein said antibody molecule is selected from the group comprising'}or a fragment or variant thereof.20) The DNA molecule of which has the nucleotide sequence of SEQ ID NO:7 claim 19 , 17 or 27.21) The DNA molecule of which has the nucleotide sequence of SEQ ID ...

Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein

Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders. 1114-. (canceled)115. A pharmaceutical combination comprising:1) a first therapeutic agent that is an isolated or synthetic dinucleotide analogue, or its salt or ester, comprising one 5-aza-cytosine as a base residue in the sequence of the dinucleotide analogue, wherein the dinucleotide analogue has a general formula of: 5′-DpG-3′ or 5′GpD-3′, wherein D is decitabine; p is a phospholinker wherein the number of phosphorus atoms in the phospholinker is one; and G is deoxyguanosine; and2) a second therapeutic agent.116. The pharmaceutical combination of claim 115 , wherein the dinucleotide analogue has the general formula of 5′-DpG-3′.117. The pharmaceutical combination of claim 115 , wherein the dinucleotide analogue has the general formula of 5′GpD-3′.118. The pharmaceutical combination of claim 115 , wherein p is a phosphorodiester linker119. The pharmaceutical combination of claim 115 , wherein the salt is a sodium claim 115 , calcium claim 115 , lithium claim 115 , potassium claim 115 , ammonium claim 115 , or trialkylammonium salt.120. The pharmaceutical ...

Abrogating proinflammatory cytokine production during oncolytic reovirus therapy

Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.

NOVEL USE

The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection. 1. Use of one or more compounds selected from the following: an α-adrenergic antagonist , an anthelmintic agent , an antifungal agent , an antimalarial agent , an antineoplastic agent , an antipsychotic agent , an antioxidant , a vasodilator and/or a vitamin , or a pharmaceutically acceptable derivative thereof , for the treatment of a microbial infection; with the proviso that when the biologically active agent is an antifungal agent , the microbial infection is a bacterial infection.2. Use according to for killing multiplying microorganisms associated with a microbial infection.3. Use according to for killing non-multiplying microorganisms associated with a microbial infection.4. Use according to for killing clinically latent microorganisms associated with a microbial infection.5. Use according to wherein the infection is a bacterial infection.6Staphylococcus aureus, Escherichia coliPseudomonas aeruginosa.. Use according to wherein the infection is caused by or7Staphylococcus aureus.. Use according to wherein the infection is caused by8. Use according to wherein the microbial infection is a fungal infection.9Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans, Histoplasma capsulatumPneumocystis jiroveci.. Use according to wherein the infection is caused by and10gardnerellaStaph. epidermidis, Strept. agalactiae, Strept. pyogenes, Escherichia coli, Klebs. pneumoniae, Klebs. oxytoca, Pr. mirabilis, Pr. ...

LIPID RAFT, CAVEOLIN PROTEIN,, AND CAVEOLAR FUNCTION MODULATION COMPOUNDS AND ASSOCIATED SYNTHETIC AND THERAPEUTIC METHODS

The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders. 2. The method of claim 1 , wherein X and Y are independently selected from the group consisting of F claim 1 , Cl claim 1 , Br claim 1 , and I; Ris —NO; Ris Cl; and Ris —NH.3. The method of claim 2 , wherein X and Y are Cl.6. The method of claim 5 , wherein X and Y are independently selected from the group consisting of F claim 5 , Cl claim 5 , Br claim 5 , and I; Ris —NO; Ris Cl; and Ris —NH.7. The method of claim 6 , wherein X and Y are Cl. This is a divisional of application Ser. No. 13/245,279, now U.S. Pat. No. 8,425,291, filed Sep. 26, 2011, which is a divisional of application Ser. No. 12/122,855, now U.S. Pat. No. 8,026,382, filed May 19, 2008, which claimed the benefit of provisional Application No. 60/938,781, filed May 18, 2007. Each of these prior applications is incorporated herein by reference in its entirety.Both platinum(II) and platinum(IV) compounds have been recognized to be useful as cancer chemotherapeutics since Rosenberg's (and colleagues') discovery in 1965 (Rosenberg, 1965). Cisplatin, cis-diaminodichloroplatinum(II), FDA-approved in 1978; and carboplatin, cis- ...

Combination Therapy With Organic Arsenicals

The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent. 2. A method of claim 1 , wherein the compound is provided as a formulation further comprising a pharmaceutical carrier claim 1 , wherein the formulation has a pH of 5 to 7.3. A method of claim 1 , wherein the compound is administered orally.4. A method of claim 1 , wherein the compound is administered intravenously.5. A method of claim 1 , wherein the compound and the one or more other therapeutic agents together are synergistic.6. A method of claim 1 , wherein the one or more other therapeutic agents are selected from bortezomib and oxaliplatin.7. A method of claim 1 , wherein the therapeutic effect of the compound and the one or more other therapeutic agents together are additive.8. A method of claim 1 , wherein the one or more other therapeutic agent is selected from dexamethasone claim 1 , irinotecan claim 1 , 5-fluorouracil claim 1 , and sorafenib.9. A method of claim 1 , wherein the cancer is selected from brain claim 1 , lung claim 1 , liver claim 1 , spleen claim 1 , kidney claim 1 , lymph node claim 1 , small intestine claim 1 , pancreas claim 1 , blood cells claim 1 , bone claim 1 , colon claim 1 , stomach claim 1 , breast claim 1 , endometrium claim 1 , prostate claim 1 , testicle claim 1 , ovary claim 1 , central nervous system claim 1 , skin claim 1 , head and neck claim 1 , esophagus claim 1 , and bone marrow cancer.10. A method of claim 1 , wherein the cancer is a hematological cancer.11. A method of claim 1 , wherein the cancer is selected from leukemia claim 1 , lymphoma claim 1 , multiple myeloma claim 1 , ...

Stabilized Angiopoietin-2 Antibodies And Uses Thereof

Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided. 1. An isolated antibody that binds to Ang-2 , wherein said antibody comprises a variable light chain , said light chain comprising a sequence selected from the group consisting of SEQ ID No:3 (MEDI1); SEQ ID No:4 (MEDI2); SEQ ID No:5 (MEDI3); SEQ ID No:6 (MEDI4); and SEQ ID No:8 (MEDI6).2. The antibody of claim 1 , wherein said antibody is an IgG1 or an IgG2 isotype antibody.3. The antibody of or claim 1 , wherein said antibody further comprises a variable heavy chain region comprising SEQ ID No:7 (MEDI5).43. The antibody of any of - claims 1 , wherein said antibody claims 1 , when produced claims 1 , exhibits a production efficiency in a mammalian host cell equal to or greater than 2 times the production efficiency of the Ang-2 antibody 3.19.3.5. The antibody of claim 4 , wherein said production efficiency is equal to or greater than 3 times the production efficiency of the Ang-2 antibody 3.19.3.6. The antibody of claim 4 , wherein said production efficiency is equal to or greater than 5 times the production efficiency of the Ang-2 antibody 3.19.3.76. A nucleic acid encoding the antibody of any of -.8. A vector comprising the nucleic acid of9. A host cell comprising the vector of .106. A pharmaceutical composition comprising the antibody of any of - and an excipient.11. A method of preventing claim 10 , treating claim 10 , or managing cancer in an animal in need thereof claim 10 , said method comprising administering to said animal a dose of an effective amount of the composition of .12. A method of preventing metastasis of cancer in an animal in need thereof claim 10 , said method comprising administering to said animal a dose of an effective amount of the composition of .13. A method of preventing recurrences of cancer in an animal in need thereof claim ...

Humanized anti-egfl7 antibodies and methods using same

The present invention concerns antibodies to EGFL7 and the uses of same.

Cancer Treatment Method

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. 1(i) a compound of formula (I″). A method of treating gastric cancer in a mammal, comprising: administering to said mammal therapeutically effective amounts of(ii) oxaliplatin, and(iii) capecitabine. This application is filed as a continuation application of U.S. application Ser. No. 13/209,889 filed Aug. 15, 2011, and U.S. application Ser. No. 12/516,661 filed May 28, 2009, now abandoned, which is a National Phase Application of International Application No. PCT/US2007/84215 filed Nov. 9, 2007, which claims priority from U.S. Provisional Application Nos. 60/867,431 filed Nov. 28, 2006; 60/943,662 filed Jun. 13, 2007; and 60/951,271 filed Jul. 23, 2007.The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines in combination with other anti-neoplastic compounds. In particular, the method relates to methods of treating cancers by administration of a combination of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine or salts or solvates thereof along with additional anti-neoplastic compounds.Effective chemotherapy for cancer treatment is a continuing goal in the oncology field. Generally, cancer results from the deregulation of the normal processes that control cell division, differentiation and apoptotic cell death. Apoptosis (programmed cell death) plays essential roles in embryonic development and pathogenesis of various diseases, such as degenerative neuronal diseases, ...

MARKER FOR DETERMINATION OF SENSITIVITY TO TRIPLET COMBINATION ANTI-CANCER AGENT

To provide a marker for determining sensitivity of a patient to an anti-cancer agent, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. 1. A marker for determining a sensitivity of a subject to an anti-cancer agent comprising oxaliplatin or a salt thereof , fluorouracil or a salt thereof , and levofolinate or a salt thereof , the marker comprising:at least one gene selected from the group consisting of ALAD gene, C20orf43 gene, CABLES 1 gene, CDC14B gene, GDA gene, HOXB6 gene, RPL7AP27 gene, TMEM18 gene, and UGT2B10 gene.2. The marker according to claim 1 , wherein the at least one gene is ALAD gene claim 1 , C20orf43 gene claim 1 , GDA gene claim 1 , TMEM18 gene claim 1 , or UGT2B10 gene.3. The marker according to claim 1 , wherein the marker predicts best tumor response (ratio).4. A method for determining a sensitivity of a subject to an anti-cancer agent comprising oxaliplatin or a salt thereof claim 1 , fluorouracil or a salt thereof claim 1 , and levofolinate or a salt thereof claim 1 , the method comprising:measuring an expression level of at least one gene selected from the group consisting of ALAD gene, C20orf43 gene, CABLES 1 gene, CDC14B gene, GDA gene, HOXB6 gene, RPL7AP27 gene, TMEM18 gene, and UGT2B10 gene in a specimen.5. The method according to claim 4 , comprising:measuring the expression level of ALAD gene, C20orf43 gene, GDA gene, TMEM18 gene, or UGT2B10 gene.6. The method according to claim 4 , wherein the method predicts best tumor response (ratio).7. The method according to claim 6 , further comprising: {'br': None, 'i': ×A−', '×B+', '×C+', '×D+', '×E . . . ,, 'Best tumor response(ratio)=0.37664+96.3608.512842.42026.810747.00'}, 'calculating best tumor response (ratio) by formulawherein A represents an expression level of ALAD gene;B represents an expression level of C20orf43 gene;C represents an expression level of GDA gene;D ...

METHODS OF TREATING CANCER

Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors. 1. A method of treatment of a cancer , the method comprising the steps ofadministering EC 145 to a patient; andadministering to the patient one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition.2. The method of wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin claim 1 , carboplatin claim 1 , topotecan claim 1 , irinotecan claim 1 , bevacizumab claim 1 , erlotinib claim 1 , lapatinib claim 1 , and pemetrexed.3. The method of wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.4. The method of wherein the additional chemotherapeutic agent is carboplatin.5. The method of wherein the additional chemotherapeutic agent is bevacizumab.6. The method of wherein the cancer is an epithelial cancer.7. The method of wherein the epithelial cancer is an ovarian claim 6 , an endometrial claim 6 , or a non-small cell lung cancer.8. The method of wherein the epithelial cancer is an ovarian cancer.9. The method of wherein the epithelial cancer is a non-small cell lung cancer.10. The method of wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.11. The method of wherein the EC145 and the chemotherapeutic agent are administered in therapeutically effective amounts.12. The method of wherein the effective ...

Treatments for cellular proliferative disorders and identification thereof

This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.

Local treatment of neurofibromas

A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.

PHARMACEUTICAL COMPOSITION

A pharmaceutical composition for intraperitoneal delivery of an anti-neoplastic agent is provided for treating cancers associated with aberrant mucin expression, preferably ovarian cancer and pancreatic, prostate, metastatic breast, bladder and lung cancers. The composition comprises nanomicelles loaded with the anti-neoplastic agent, and antibodies such as anti-MUC16, anti-MUC1 or anti-MUC4 are conjugated to these nanomicelles. The antibody-bound nanomicelles are optionally embedded in a biodegradable pH- and thermo-responsive hydrogel capable of sol-gel transition at body temperature. The pharmaceutical composition is implantable in the peritoneum, where it transforms into a semi-solid gel at the body's core temperature. In response to pH, the hydrogel swells and releases the antibody-bound nanomicelles. The nanomicelles specifically target mucin antigens on cancer cells. The anti-mucin antibodies can be internalized by the tumour cells, enabling the drug-loaded nanomicelles to gain entry and deliver the chemotherapeutic drugs inside the tumour cell. 1. A pharmaceutical composition for the delivery of an anti-neoplastic agent to a human or animal body , the composition comprising:nanoparticles comprising an anti-neoplastic agent; andmucin antibodies, wherein the particles are encapsulated in a thermal- and pH-responsive hydrogel composition which is liquid at about ambient room temperature and in a solid or semi-solid form at body temperature and which swells in an acidic environment and thereby releases the nanoparticles.2. The pharmaceutical composition according to claim 1 , wherein the mucin antibodies are conjugated to the nanoparticles.3. The pharmaceutical composition according to claim 1 , wherein the antibodies are anti-MUC16 antibodies.4. The pharmaceutical composition according to claim 1 , wherein the antibodies are anti-MUC 1 antibodies.5. The pharmaceutical composition according to claim 1 , wherein the antibodies are anti-MUC4 antibodies.6. The ...

Multi-encapsulated formulations made with oxidized cellulose

A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.

Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity

Treating cancer of a organ located in a mesothelium-lined body cavity (i.e., lung, kidney, adrenal gland, ovary, prostate, pancreas or bladder cancer) by irrigating the mesothelium-lined body cavity with a solution containing a recombinant viral gene therapy vector bearing an interferon transgene, optionally administered shortly before administering chemotherapy and/or COX-2 inhibitor.

HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS

Methods of treating a head and neck cancer are disclosed. 1. A method of treating a subject having a squamous cell carcinoma of the head and neck (HNSCC) , comprising:acquiring knowledge that the subject is negative for the human papillomavirus (HPV−); andadministering to the subject a cyclin dependent kinase (CDK) inhibitor,thereby treating the HNSCC in the subject.2. The method of claim 1 , wherein the CDK inhibitor inhibits one or both of CDK4 or CDK6.3. The method of claim 1 , wherein the CDK inhibitor is LEE011 claim 1 , LY-2835219 or PD 0332991.4. The method of claim 1 , wherein the CDK inhibitor is LEE011.5. The method of claim 1 , wherein the CDK inhibitor is LY-2835219.6. The method of claim 1 , wherein the CDK inhibitor is PD 0332991.7. The method of claim 1 , wherein the CDK inhibitor is Indisulam claim 1 , AZD5438 claim 1 , SNS-032 claim 1 , SCH 727965 claim 1 , JNJ-7706621 claim 1 , indirubin or Seliciclib.8. The method of claim 1 , wherein the subject is HPV− and has a mutation in a cell cycle gene chosen from cyclin dependent kinase inhibitor 2A (CDKN2A) claim 1 , cyclin dependent kinase inhibitor 2B (CDKN2B) claim 1 , Cyclin E1 (CCNE1) claim 1 , Cyclin D1 (CCND1) claim 1 , Cyclin D2 (CCND2) claim 1 , Cyclin D3 (CCND3) claim 1 , cyclin dependent kinase 4 (CDK4) or cyclin dependent kinase 6 (CDK6) claim 1 , or a gene described in Table 1 or Table 4.9. The method of claim 1 , wherein the subject has one or more of:(i) a loss-of-function mutation in the CDKN2A gene;(ii) a gain-of-function mutation in the CCND1 gene;(iii) a mutation or a mutant polypeptide described in Table 1 or 4; or(iv) a mutant CDKN2A, CDKN2B or CCND1 polypeptide.10. The method of claim 1 , further comprising acquiring knowledge of whether the subject has a mutation in a cell cycle gene chosen from CDKN2A claim 1 , CDKN2B claim 1 , CCNE1 claim 1 , CCND1 claim 1 , CCND2 claim 1 , CCND3 claim 1 , CDK4 or CDK6 claim 1 , or a gene described in Table 1 or Table 4.11. The method of claim 10 ...

METHODS OF TREATING BLADDER CANCER

The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin. 1: A method of treating bladder cancer in an individual in need thereof , comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin.2: The method of claim 1 , wherein the bladder cancer is non-muscle-invasive bladder cancer.3: The method of claim 1 , wherein the bladder cancer is refractory to treatment with BCG claim 1 , mitomycin C claim 1 , or interferon.4: The method of claim 1 , wherein the nanoparticle composition is administered intravesicularly.5: The method of claim 4 , wherein the nanoparticle composition is administered at the dose of about 150 mg to about 500 mg.6: The method of claim 4 , wherein the nanoparticle composition is administered once weekly.7: The method of wherein the bladder cancer is platinum-refractory bladder cancer.8: The method of claim 7 , wherein the platinum-refractory bladder cancer is metastatic bladder cancer.9: The method of claim 7 , wherein the nanoparticle composition is administered intravenously.10: The method of claim 9 , wherein the nanoparticle composition is administered at the dose of about 260 mg/m2 to about 300 mg/m2.11: The method of claim 9 , wherein the nanoparticle composition is administered once every three weeks.12: A method of treating bladder cancer in an individual claim 9 , comprising concurrently administering to the individual (a) an effective amount of a composition comprising nanoparticles comprising a taxane and albumin; (b) an effective amount of a platinum-based agent; and (c) an effective amount of an antimetabolite.13: The method of claim 12 , wherein the bladder cancer is platinum-refractory bladder cancer.14: The method of claim 12 , wherein the cancer is locally ...

PREVENTING PULMONARY RECURRENCE OF CANCER WITH LIPID-COMPLEXED CISPLATIN

The described invention provides methods for treating pulmonary cancer in a subject, by administering to the subject by inhalation a composition of inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin. 1. A method for treating a pulmonary cancer in a subject in need thereof , comprising:(1) surgically excising the pulmonary cancer so that the subject is characterized as being macroscopically disease-free; and{'sup': 2', '2, '(2) administering by inhalation an inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin at a dose of from 18 mg/mto 36 mg/m,'}wherein the ILC is dispersed throughout an aqueous phase of a dispersion.2. The method according to claim 1 , wherein the pulmonary cancer is pulmonary metastatic disease of osteosarcoma.3. The method according to claim 2 , wherein the pulmonary metastatic disease of osteosarcoma is recurrent osteosarcoma.4. The method according to claim 1 , wherein the ILC further comprises liposomes.5. The method according to claim 4 , wherein the liposomes comprise a sterol and a phosphatidylcholine.6. The method according to claim 5 , wherein the sterol is cholesterol.7. The method according to claim 5 , wherein the phosphatidylcholine is dipalmitoylphosphatidylcholine (DPPC).8. The method according to claim 1 , wherein the administering by inhalation is performed by a nebulizer.9. The method according to claim 1 , wherein the administering by inhalation is at a dose of 36 mg/m.10. The method according to claim 1 , wherein the administering by inhalation is at a dose of at least 24 mg/m.11. The method according to claim 1 , wherein the administering by inhalation is at a dose of at least 18 mg/m.12. The method according to claim 1 , wherein the dispersion has a particle size of ≦1 μm.13. The method according to claim 1 , wherein the administering by inhalation occurs at a rate of 0.3 mL/minute for 20 minutes.14. The method according to claim 1 , wherein the administering by inhalation occurs 1 ...

Method of therapy

Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also relates to methods of determining when a therapy to treat a disease characterized by the production of regulator cells should be administered to a patient.

Antioxidant therapy with a whole, leech saliva extract

Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.

Exosomal compositions and methods for the treatment of disease

An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.

Treatment of Neoplasia

A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.

COMBINING ADENOVIRUS AND CHEMOTHERAPEUTIC AGENTS FOR TREATING CANCER

The invention relates to oncolytic adenovirus vector and chemotherapeutic agents. More specifically, the invention relates to oncolytic adenovirus vector and chemotherapeutic agents for use in a cancer therapy. The combination therapy as described herein has superior safety properties and have effective therapeutic activity. 1. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma , wherein the virus is administered in combination with two chemotherapeutic agents to a patient.2. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 1 , wherein the two chemotherapeutic agents are either Pemetrexed and Cisplatin or Pemetrexed and Carboplatin.3. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 2 , wherein the molar ratio between Pemetrexed and Cisplatin is from 10:0.75 to 10:3.4. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 3 , wherein the molar ratio between Pemetrexed and Cisplatin is 10:1.5.5. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 2 , wherein the molar ratio between Pemetrexed and Carboplatin is from 5:8 to 5:2.6. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 5 , wherein the molar ratio between Pemetrexed and Carboplatin is 5:4.7. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 1 , wherein the amount of the virus is from 5×10to 5×10VP.8. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 7 , wherein the virus is administered in an amount of 3×10VP/5 ml.9. ONCOS-102 adenovirus for use in the treatment of human malignant mesothelioma according to claim 1 , wherein the chemotherapeutic agents and the virus are administered in effective amounts.10. ONCOS-102 adenovirus for use in the treatment of human ...

SYSTEMS AND METHODS FOR TREATING CANCER

Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is LKB1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising contacting the cancer cells with a therapeutically effective amount of a Wee1 inhibitor and a therapeutically effective amount of a second pharmaceutical composition. Embodiments of the invention also provide a method of prognosing or determining the severity of cancer in a subject comprising (a) determining the presence or absence of LKB1 in the cancer cells of the subject; and (b) prognosing the severity of cancer based on the presence of LKB1 deficiency in the cancer cells of the subject. 1. A method of treating adenocarcinoma in a subject , wherein the adenocarcinoma cells are LKB1 deficient , the method comprising the steps of contacting the LKB1 deficient adenocarcinoma cells with a therapeutically effective amount of a Wee1 kinase inhibitor.2. The method of claim 1 , wherein the adenocarcinoma is lung cancer.3. The method of claim 2 , wherein the lung cancer is non-small cell lung cancer.4. The method of claim 1 , wherein the Wee1 kinase inhibitor is AZD1775.5. The method of and further comprising contacting the LKB1 deficient adenocarcinoma cells with a therapeutically effective amount of a second pharmaceutical composition.6. The method of claim 5 , wherein the second pharmaceutical composition comprises at least one of the following: a DNA-damaging ...

ADMINISTRATION OF A THIOL-BASED CHEMOPROTECTANT COMPOUND

A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver. 1. A method for treating or mitigating the side effects of cytotoxic cancer therapy comprising administering sodium thiosulfate (STS) in conjunction with a cis-platinum compound , wherein the STS is administered about 4 hours after administration of the cis-platinum compound , and wherein the STS is at a dose from 5 g/mto 40 g/m.2. The method for treating or mitigating the side effects of cytotoxic cancer therapy of wherein the STS is administered intravenously.3. The method for treating or mitigating the side effects of cytotoxic cancer therapy of wherein the STS is administered intra-arterially.4. The method for treating or mitigating the side effects of cytotoxic cancer therapy of wherein the cancer is a cancer located in the brain claim 3 , head or neck.5. A method for treating or mitigating the side effects of cytotoxic cancer therapy comprising administering sodium thiosulfate (STS) in conjunction with a cis-platinum compound claim 3 , wherein the STS is administered from about 4 hours to 8 hours after administration of the cis-platinum compound claim 3 , and wherein the STS is at a dose from 5 g/mto 40 g/m.6. A method for treating or mitigating the side effects of cytotoxic cancer therapy comprising administering sodium thiosulfate (STS) in conjunction with a cis-platinum compound claim 3 , wherein the STS is administered about 4 hours after administration of the cis-platinum compound claim 3 , and wherein the STS is administered ...

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

APPLICATIONS OF PAIR-PRODUCTION FOR IMPROVED RADIOTHERAPY

The present invention relates to the treatment of cancer by irradiation by high energy photons, wherein the cancer has been infused with a heavy metal. The invention further relates to the use of pair-production for increased cancer cell destruction. 1. A method of treating cancer in a patient , wherein the patient is a mammal , comprising the steps of:a. administering to the patient a pharmaceutically acceptable composition comprising a heavy metal organometallic compound;b. allowing a time interval to pass; andc. irradiating the area of the patient previously identified as the location of the cancer with high energy photons sufficient to induce positron-electron pair production.2. The method of claim 1 , wherein the patient is a human.3. The method of claim 1 , wherein the method includes treating a solid tumor in a patient.4. The method of claim 1 , wherein the treatment includes killing cells of the tumor.5. The method of claim 1 , wherein the heavy metal organometallic compound comprises one or more of tungsten claim 1 , platinum claim 1 , gold claim 1 , mercury claim 1 , cadmium claim 1 , arsenic claim 1 , chromium claim 1 , thallium claim 1 , and lead.6. The method of claim 1 , wherein the heavy metal organometallic compound comprises a metal having low toxicity.7. The method of claim 1 , wherein the heavy metal organometallic compound comprises tungsten.8. The method of claim 1 , wherein the time interval is from 1 minute to 24 hours.9. The method of claim 1 , wherein the time interval is from 5 minutes to 12 hours.10. The method of claim 1 , wherein the time interval is from 10 minutes to 6 hours.11. The method of claim 1 , wherein the time interval is from 20 minutes to 3 hours.12. The method of claim 1 , wherein the time interval is from 20 minutes to 2 hours.13. The method of claim 1 , wherein the time interval is from 30-90 minutes.14. The method of claim 1 , wherein the time interval is from 45-75 minutes.15. The method of claim 1 , wherein the time ...

FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES

Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent. 1. A method of treating lung cancer in a human subject comprising administering to the subject an effective amount of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule and at least one additional therapeutic agent selected from docetaxel , paclitaxel , vincristine , carboplatin , and topotecan , wherein the FGFR1 ECD fusion molecule comprises an FGFR1 ECD comprising an amino acid sequence selected from SEQ ID NOs: 1 to 4 and a fusion partner.2. The method of claim 1 , wherein the at least one additional therapeutic agent is docetaxel.3. The method of claim 1 , wherein the at least one additional therapeutic agent is paclitaxel.4. (canceled)5. (canceled)6. The method of claim 1 , wherein the at least one additional therapeutic agent is vincristine.7. (canceled)8. The method of claim 1 , wherein the at least one additional therapeutic agent is topotecan.9. The method of claim 1 , wherein the method comprises administering to the subject at least two additional therapeutic agents selected from docetaxel claim 1 , paclitaxel claim 1 , vincristine claim 1 , carboplatin claim 1 , ...

MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS

The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject. 173-. (canceled)77. The method of claim 74 , wherein said nanocarrier has embedded in claim 74 , encapsulated in claim 74 , or tethered to a therapeutic agent selected from the group consisting of doxorubicin claim 74 , cisplatin claim 74 , oxaliplatin claim 74 , carboplatin claim 74 , 5-fluorouracil claim 74 , gemcitibine and a taxane.78. The method of claim 74 , wherein said nanocarrier has embedded in claim 74 , encapsulated in claim 74 , or tethered to a diagnostic agent selected from the group consisting of a radioactive agent claim 74 , a fluorescent agent claim 74 , and a contrast agent.82. The method of claim 79 , wherein MMPhas an ICof about 13 nM or lower.83. The method of claim 80 , wherein MMPhas an ICof about 13 nM or lower.84. The method of claim 81 , wherein MMPhas an ICof about 13 nM or lower.85. The method of claim 79 , wherein the administration of the composition inhibits growth of the tumor cells by at least 50%.86. The method of claim 80 , wherein the administration of the composition reduces the tumor burden by at least 50%. The present application claims priority to U.S. Provisional Patent Application No. 61/565,461, filed Nov. 30, 2011, the entirety of which is incorporated herein by reference.NOT APPLICABLENOT APPLICABLECancer is a class of diseases that can affect people of all ages. Accordingly, there is considerable effort to provide therapies that can treat or diagnose cancer in patients. Targeted delivery of nanocarriers in the body has been discussed recently as a potential new avenue in drug delivery and diagnostic imaging techniques. Unfortunately, obstacles still exist in making nanocarrier based-products that can effectively treat or diagnose cancer.Many if not all solid tumors either express matrix metalloproteinase (MMP) enzymes on their surface or excrete it into the ...

NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBODY WHICH BINDS THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II

The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions. 1. Pharmaceutical composition comprising , as active ingredient , in combination with a pharmaceutically acceptable vehicle ,an anticancer agent, andan antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II).2. Pharmaceutical composition according to claim 1 , in which said antibody is a polyclonal antibody or a monoclonal antibody claim 1 , and preferably a chimeric 12G4 or humanized 12G4 monoclonal antibody.3. Composition according to claim 1 , in which said monoclonal antibody is a humanized 12G4 antibody claim 1 , or a fragment of humanized 12G4 monoclonal antibody claim 1 , in which said humanized 12G4 monoclonal antibody is mutated and comprises at least one mutation in the light and/or heavy chain claim 1 , and said mutated humanized 12G4 monoclonal antibody in particular possesses affinity for AMHR-II characterized by a Kpreferably less than 10M claim 1 , in particular less than 10M claim 1 , in particular in the range from 10M to 10M.5. Pharmaceutical composition according to claim 4 , in which said mutated humanized 12G4 monoclonal antibody comprises or is constituted by: a variable region the amino acid sequence of which is represented by SEQ ID NO: 7 or SEQ ID NO: 8,', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 3, 'a) a light chain comprising or constituted by a variable region the amino acid sequence of which is represented by SEQ ID NO: 9 or SEQ ID NO: 10', 'a constant region the amino acid sequence of which is represented by SEQ ID NO: 6, 'b) a heavy chain comprising or constituted by6. Pharmaceutical composition according to claim 4 , in which the mutated humanized 12G4 monoclonal antibody is produced by the 3C23K clone or in which the ...

IMPROVING ANTI-PD-1 CANCER THERAPY

Materials and methods for identifying and treating cancer patients who are likely to respond to chemo-immunotherapy (CIT) and other cancer treatments are provided herein, including materials and methods for using CX3CR1 to identify PD-1 therapy-responsive CD8+ T cells that withstand the toxicity of chemotherapy during combined CIT. 1. A method comprising:{'sup': +', '+', '+', '+, 'measuring the percentage of CX3CR1 cells and the percentage of Bim cells within a first population of CD8 T cells obtained from a subject having a tumor, wherein said first population of CD8 T cells was obtained prior to treatment of said subject with PD-1 blockade therapy;'}{'sup': +', '+', '+', '+, 'measuring the percentage of CX3CR1 cells and the percentage of Bim cells within a second population of CD8 T cells obtained from the subject, wherein said second population of CD8 T cells was obtained after treatment of the subject with PD-1 blockade therapy;'}{'sup': +', '+', '+', '+', '+', '+, 'identifying said subject as having a percentage of CX3CR1 cells within said second population that is increased by at least a predetermined CX3CR1 threshold relative to said percentage of CX3CR1 cells within said first population and as having a percentage of Bim cells within said second population that is decreased by at least a predetermined Bim threshold relative to said percentage of Bim cells within said first population; and'}treating said subject with a therapy to increase tumor immunogenicity.23-. (canceled)4. The method of claim 1 , wherein said predetermined CX3CR1 threshold is an increase of at least 80% and said predetermined Bim threshold is a decrease of at least 20%.5. The method of claim 1 , wherein said first and second populations of CD8 T cells are from the peripheral blood of said subject claim 1 , or wherein said first and second populations of CD8 T cells are from said tumor.6. (canceled)7. The method of claim 1 , wherein said subject is a human.8. The method of claim 1 , ...

INHIBITORS OF ARG1 AND/OR ARG2

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein. 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , hydrate claim 1 , or solvate thereof claim 1 , wherein:{'sup': '4a', 'X is N or CR;'}{'sup': '1', 'sub': '1-8', 'each Ris independently H or Calkyl;'}{'sup': '2', 'sub': '3', 'Ris H or CH;'}{'sup': 3', '3', 'a, 'sub': '1-8', 'each Ris independently H or Calkyl; or two Rgroups are joined together to form a 5 or 6-membered ring which is unsubstituted or substituted with from 1 to 4 R;'}{'sup': 4a', '4b', '4c', '4d', '1', '1', '2', '5a', '1', '5b', '5c, 'sub': 1-8', '1-8', '1-8', '1-8, 'each R, R, Rand Ris independently selected from the group consisting of H, halogen, CN, Calkyl, Calkoxy, Chydroxyalkyl, Chaloalkyl, —X—Y, —X—SORand —X—NRR;'}{'sup': 5a', '5b', '5c', '5b', '5c', 'b, 'sub': 1-8', '1-8', '1-8', '3-7', '3-7, 'each R, Rand Ris independently selected from the group consisting of H, Calkyl, Chaloalkyl, CalkylC(O)—, Ccycloalkyl, 3- to 7-membered heterocycloalkyl, aryl, heteroaryl and an amino acid, or Rand Rare joined together to form a 4- to 6-membered ring; and wherein each of the 4- to 6-membered ring, Ccycloalkyl or 3- to 7-membered heterocycloalkyl, aryl and heteroaryl, are unsubstituted or substituted with from 1 to 4 R;'}{'sup': 1', 'c, 'sub': '1-6', 'each Xis a bond or Calkylene which is unsubstituted or substituted with 1 to 4 R;'}{'sup': a', 'b', 'c', 'c, 'sub': 2', '1-4', '1-4', '3-6', '3-6, 'each R, Rand Ris independently halogen, CN, OH, NH, Calkyl, Chaloalkyl, Ccycloalkyl and phenyl, or two Rare combined to form a Ccycloalkyl;'}{'sup': 'd', 'each Y is ...

Methods for treatment of cancer with an anti-tigit antagonist antibody

The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.

OX40 ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF

Provided are a murine or human-mouse chimeric antibody targeting OX40 and a preparation method therefor, wherein the antibody binds to the OX40 antigen and has an anti-tumor activity and other activities. 1. A heavy chain variable region of an antibody having a complementarity determining region CDR selected from the group consisting of:a VH-CDR1 as shown in SEQ ID NO. 10n+3,a VH-CDR2 as shown in SEQ ID NO. 10n+4, anda VH-CDR3 as shown in SEQ ID NO. 10n+5;wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;wherein any one of the above amino acid sequences further includes a derivative sequence that is optionally added, deleted, modified, and/or substituted for at least one amino acid and can retain the binding affinity of OX40.24-. (canceled)5. An antibody having:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(1) a heavy chain variable region of ; and/or'}(2) a light chain variable region having a complementarity determining region CDR selected from the group consisting of:a VL-CDR1 as shown in SEQ ID NO. 10n+8,a VL-CDR2 as shown in SEQ ID NO. 10n+9, anda VL-CDR3 as shown in SEQ ID NO. 10n+10;wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;wherein any one of the above amino acid sequences further includes a derivative sequence that is optionally added, deleted, modified, and/or substituted for at least one amino acid and can retain the binding affinity of OX40.7. The antibody of claim 5 , wherein the heavy chain variable region of the antibody contains the amino acid sequence as shown in SEQ ID NO. 101 claim 5 , 1 claim 5 , 11 claim 5 , or 21; and/or the light chain variable region of the antibody contains the amino acid sequence as shown in SEQ ID NO. 103 claim 5 , 6 claim 5 , 16 or 26.9. A recombinant protein comprising:{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, '(i) an antibody of ; and'}(ii) an optional tag sequence to assist in expression and/or purification.10. A polynucleotide encoding a polypeptide of{'claim-ref': {'@ ...

METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation. 1. A method for treating cancer , the method comprising a therapeutically effective amount of a PARP inhibitor and/or an alkylating agent to a human patient identified as having , in a tumor sample obtained from the patient , a number , per genome , of large scale transitions (LSTs) greater than a predetermined threshold number of LSTs , wherein an LST is a breakpoint between two genomic regions of different copy number , each such genomic region greater than or equal to 3 and less than 6 megabases long.2. The method of claim 1 , wherein said PARP inhibitor and/or alkylating agent is selected from the group consisting of iniparib claim 1 , olaparib claim 1 , rucaparib claim 1 , CEP 9722 claim 1 , MK 4827 claim 1 , BMN-673 claim 1 , 3-aminobenzamide claim 1 , platinum complexes claim 1 , chlormethine claim 1 , chlorambucil claim 1 , melphalan claim 1 , cyclophosphamide claim 1 , ifosfamide claim 1 , estramustine claim 1 , carmustine claim 1 , lomustine claim 1 , fotemustine claim 1 , streptozocin claim 1 , busulfan claim 1 , pipobroman claim 1 , procarbazine claim 1 , dacarbazine claim 1 , thiotepa and temozolomide.3. The method of claim 1 , wherein the cancer is selected from breast cancer claim 1 , ovary cancer claim 1 , pancreas cancer claim 1 , head and neck carcinoma and melanoma.4. The method of claim 1 , wherein the cancer is breast cancer.5. The method of claim 1 , wherein the cancer is basal-like breast cancer.6. The method of claim 1 , wherein the patient is identified by detecting claim 1 , in the tumor sample claim 1 , the number of LSTs per genome.7. The method of claim 6 , wherein the number of LSTs per genome is detected by detecting copy number for at least 500 Single Nucleotide Polymorphism (SNP) loci.8. The method of claim 6 , wherein the number of LSTs per genome is detected by ...

VELIPARIB IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care. 1. A method for the treatment of ER-negative , PR-negative , and HER-2 negative cancer of the breast in a subject , comprising administering to the subject in need thereof a first chemotherapy segment comprising administeringa therapeutically effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide.2. The method of claim 1 , wherein the therapeutically effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide is administered twice a day continuously for twelve weeks.3. The method of claim 2 , wherein 40 mg-125 mg of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide is administered to the subject twice a day continuously for twelve weeks.4. The method of claim 3 , wherein 50 mg of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide is administered to the subject twice a day continuously for twelve weeks.5. The method of claim 1 , wherein the first chemotherapy segment additionally comprises(a) a therapeutically effective amount of carboplatin.6. The method of claim 5 , wherein the subject is undergoing standard chemotherapy.7. The method of claim 6 , wherein the first chemotherapy segment is concurrently administered with standard chemotherapy.8. The method of claim 7 , wherein the standard chemotherapy is a therapeutically effective amount of paclitaxel.9. The method of claim 8 , wherein the therapeutically effective amount of paclitaxel is administered on day 1 of twelve 7-day cycles.10. The method of claim 9 , wherein 80 mg/mpaclitaxel is administered on day 1 of twelve 7-day cycles.11. The method of claim 5 , wherein the therapeutically ...

PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof. 2. The compound of claim 1 , wherein the conjugation between Rand the functional group takes place in vivo.3. The compound of claim 1 , wherein the conjugation between Rand the functional group is performed prior to administration in vivo.4. The compound of claim 1 , wherein the protein is albumin.8. The compound of any one of - claim 1 , wherein Rand Reach is Cl.9. The compound of any one of - claim 1 , wherein Rand Rare joined to form an oxalate.10. The compound of any one of - claim 1 , wherein Ris alkyl.11. The compound of - claim 1 , wherein Ris methyl or ethyl.13. A pharmaceutical composition comprising a compound according to any one of to and a pharmaceutically acceptable carrier.14. A method of treating cancer selected from lung cancer including small cell lung cancer claim 1 , non-small cell lung cancer and squamous cell lung cancer claim 1 , breast cancer claim 1 , colorectal cancer claim 1 , colon cancer claim 1 , ovarian cancer claim 1 , pancreatic cancer claim 1 , bladder cancer claim 1 , prostate cancer claim 1 , cervical cancer claim 1 , renal cancer claim 1 , leukemia claim 1 , central nervous system cancers claim 1 , myeloma claim 1 , melanoma claim 1 , mesothelioma claim 1 , stomach cancer claim 1 , rectal cancer claim 1 , cancer of the large intestine claim 1 , cancer of the small intestine claim 1 , esophageal cancer claim 1 , uterine cancer claim 1 , head and neck cancer claim 1 , endometrial cancer claim 1 , eye cancer claim 1 , thyroid cancer claim 1 , testicular cancer claim 1 , bile duct cancer ...

Anti-igf antibodies

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

COMBINATION BETWEEN TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, AN ANTITUMOR PLATINIUM COMPLEX, AND AN IMMUNE CHECKPOINT MODULATOR

A combination comprising: 128-. (canceled)29. A combination comprising:an FTD-TPI drug,an anti-tumor platinum complex,and an immune checkpoint modulator.30. The combination according to claim 29 , which is formulated for concomitant or sequential therapeutic use.31. The combination according to claim 29 , wherein the anti-tumor platinum complex is selected from cisplatin claim 29 , carboplatin and oxaliplatin.32. The combination according to claim 29 , wherein the anti-tumor platinum complex is oxaliplatin.33. The combination according to claim 29 , wherein the immune checkpoint modulator is selected from an anti-PD-1 antibody or an anti-PD-L1 antibody.34. The combination according to claim 29 , wherein the immune checkpoint modulator is selected from nivolumab and pembrolizumab.35. The combination according to claim 29 , wherein the immune checkpoint modulator is nivolumab.36. The combination according to claim 30 , wherein each component is present at a dose that is 50 to 100% of the recommended dose for each component when administered alone.37. The combination according to claim 30 , which is formulated for concomitant administration of the three components.38. The combination according to claim 30 , which is formulated for sequential administration of the three components.39. A method of treating cancer in a subject in need thereof claim 29 , comprising administration of the combination according to claim 29 , alone or in combination with one or more pharmaceutically acceptable excipients claim 29 , wherein the components of the combination are administered concomitantly or sequentially.40. The method according to claim 39 , wherein administration of the immune checkpoint immunomodulator is initiated later than administration of the two other components.41. The method according to claim 39 , wherein the treatment cycle is 14 days.42. The method according to claim 39 , wherein the FTD-TPI drug is orally administered at a dose of 20 to 80 mg/m/day in terms of FTD ...

Combination Therapy Comprising Varlitinib and an Anticancer Agent

In one aspect the present disclosure provides a method of sensitizing a cancer patient to chemotherapy by administering a combination therapy comprising; 124.-. (canceled)27. A method according to claim 25 , wherein the compound of formula (I) is provided as the free base.28. A method according to claim 25 , wherein the pyrimidine analogue is selected from the group comprising 5-fluorouracil (5-FU) claim 25 , capecitabine (Xeloda®) claim 25 , floxuridine claim 25 , gemcitabine claim 25 , cytarabine claim 25 , decitabine claim 25 , raltitrexed (tomudex) hydrochloride claim 25 , cladribine and 6-azauracil.29. A method according to claim 25 , wherein the pyrimidine analogue is 5-FU.30. A method according to claim 25 , wherein the pyrimidine analogue is gemcitabine.31. A method according to claim 25 , wherein the pyrimidine analogue is capecitabine.32. A method according to claim 25 , wherein the chemotherapeutic agent or combination of chemotherapeutic agents is selected from FOLFOX claim 25 , GEMOX claim 25 , FOLFIRI and FOLFIRINOX.33. A method according to claim 25 , wherein the combination therapy further comprises a platinum based chemotherapeutic agent.34. A method according to claim 33 , wherein the platinum based chemotherapeutic agent is selected from the group comprising cisplatin claim 33 , carboplatin claim 33 , oxaliplatin claim 33 , satraplatin claim 33 , picoplatin claim 33 , nedaplatin claim 33 , triplatin claim 33 , lipoplatin and combinations thereof.35. A method according to claim 25 , wherein the combination therapy further comprises cisplatin.36. A method according to claim 25 , wherein the combination therapy further comprises oxaliplatin.37. A method according to claim 25 , wherein the cancer is an epithelial cancer.38. A method according to claim 25 , wherein the cancer is selected from gastric cancer claim 25 , hepatocellular carcinoma claim 25 , choloangiocarcinoma claim 25 , colorectal cancer and bladder cancer.39. A method according to claim ...

Combinational Liposome Compositions for Cancer Therapy

The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome. 124-. (canceled)25. A first composition comprising a first liposome comprising a therapeutic agent , wherein the therapeutic agent is selected from the group consisting of: cisplatin , oxaliplatin , carboplatin , gemcitibine , 5-fluorouracil , doxorubicin , and a taxane; anda second composition comprising a lipid nanoparticle comprising a non-ionic triggering agent for sequential or concurrent use with the first composition in delivering a therapeutic agent to a subject in need thereof,whereby release of the therapeutic agent from the liposome following administration of the lipid nanoparticle is increased, relative to the release of the therapeutic agent from the liposome without administration of the lipid nanoparticle.26. The first composition of claim 25 , wherein the first liposome comprises one or more lipids selected from the group consisting of: a phospholipid claim 25 , a steroid claim 25 , and a cationic lipid.27. The first composition of claim 26 , wherein the phospholipid is selected from the group consisting of: a phosphatidylcholine claim 26 , a phosphatidylglycerol claim 26 , a phosphatidylethanolamine claim 26 , a phosphatidylserine claim 26 , a phosphatidylinositol claim 26 , and a phosphatidic acid.28. The first composition of claim 27 , wherein the phosphatidylcholine is distearoyl phosphatidyl choline (DSPC).29. The first composition of claim 27 , wherein the phosphatidylglycerol is distearoyl phosphatidyl glycerol (DSPG).30. The first composition of claim 27 , wherein the phosphatidylethanolamine is DSPE-PEG(2000).31. The first composition of claim 26 , wherein the steroid is cholesterol.32. The first composition ...

POXVIRAL ONCOLYTIC VECTORS

The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. 131.-. (canceled)32. A method for treating a disease state comprising administering to an host organism or cell which is in need a poxvirus comprising a defective I4L and/or F4L gene or a composition comprising said poxvirus with the proviso that said poxvirus is not NYVAC.33. A method for treating a disease state comprising administering to an host organism or cell which is in need a poxvirus comprising a defective I4L and/or F4L gene and a defective J2R or a composition comprising said poxvirus with the proviso that said poxvirus is not NYVAC.34. The method as defined by or , further comprising administering to said host organism or cell a topoisomerase I inhibitor selected from the group consisting of irinotecan , 7-ethyl-10-hydroxy-camptothecin and topotecan.35. The method as defined by claim 34 , wherein said topoisomerase I inhibitor is irinotecan.36. The method as defined by wherein said poxvirus or composition is administered via the systemic route.37. The method as defined by wherein said poxvirus further comprises a suicide gene.38. The method as defined by wherein said suicide gene encodes a polypeptide comprising an amino acid sequence substantially as represented in the sequence identifier SEQ ID NO: 1 (FCU1) or SEQ ID NO: 3 (coda:upp).39. The method as defined by further comprising an additional step in which a pharmaceutically acceptable quantity of a prodrug is administered to said host organism or cell.40. The method as defined by wherein said prodrug is 5 fluorocytosine.41. The method as defined by wherein the administration of said prodrug takes place preferably at least 3 days claim 39 , more preferably at least 4 days and even more preferably at least 5 days after the administration ...

COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. 1. A composition comprising: (a) nanoparticles comprising paclitaxel and albumin and (b) an anti-VEGF antibody.2. The composition of claim 1 , wherein the anti-VEGF antibody is bevacizumab.3. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is between about 0.01:1 and about 100:1.4. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is less than about 30:1.5. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is less than about 10:1.6. The composition of claim 2 , wherein the weight ratio of the paclitaxel and the bevacizumab is less than about 10:1.7. The composition of claim 1 , wherein the weight ratio of the paclitaxel and the anti-VEGF antibody is about 2:1 to about 3:1.8. The composition of claim 2 , wherein the weight ratio of the paclitaxel and the bevacizumab is about 2:1 to about 3:1.9. The composition of claim 1 , wherein the composition further comprises a platinum-based agent.10. The composition of claim 9 , wherein the platinum-based agent is carboplatin.11. The composition of claim 1 , wherein the nanoparticles comprise paclitaxel coated with albumin.12. The composition of claim 8 , wherein the nanoparticles comprise paclitaxel coated with albumin.13. The composition of claim 1 , wherein the average diameter of the nanoparticles in the composition is no greater ...

INHIBITION OF DYNAMIN RELATED PROTEIN 1 TO PROMOTE CELL DEATH

The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting Drp1. It is based, at least in part, on the discoveries that (i) Drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that Drp1 inhibition results in a disruption of the cell cycle and DNA aberrancies; (ii) inhibition of both Drp1 and ATR are synthetic lethal causing increased DNA damage and apoptotic cell death; and (iii) even in resistant cell lines, Drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies. 2. The method of claim 1 , further comprising administering claim 1 , to the cancer cell claim 1 , an effective amount of a second antiproliferative agent.3. The method of where the second antiproliferative agent is a platinum compound.4. The method of where the platinum compound is cisplatin.5. The method of where the platinum compound is carboplatin.6. The method of where the cisplatin is bound to an albumin carrier.7. The method of where compound D is bound to an albumin carrier.8. The method of where compound D is bound to a cyclodextrin carrier.10. The method of claim 9 , where the cancer is selected from the group consisting of breast cancer claim 9 , lung cancer claim 9 , ovarian cancer claim 9 , glioblastoma claim 9 , squamous cell carcinoma of the head and neck claim 9 , melanoma and colon cancer.11. The method of claim 9 , further comprising administering claim 9 , to the subject claim 9 , an effective amount of a second antiproliferative agent.12. The method of where the second antiproliferative agent is a platinum compound.13. The method of where the platinum compound is cisplatin.14. The method of where the cisplatin is bound to an albumin carrier.15. The method of where the platinum ...

PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds. 2. The composition of wherein the carrier comprises water and optionally a buffer claim 1 , a cyclodextrin claim 1 , or a combination thereof.3. The composition of wherein the cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.4. The composition of wherein the concentration of PAC-1 is about 2 μM to about 50 μM.5. The composition of wherein the concentration of the second active agent is about 25 nM to about 1 mM.6. The composition of wherein the second active agent is etoposide and the concentration of etoposide is about 2 μM to about 50 μM.7. The composition of wherein the second active agent is bortezomib and the concentration of bortezomib is about 50 nM to about 20 μM.8. The composition of wherein the second active agent is staurosporine and the concentration of staurosporine is about 25 nM to about 200 nM.9. The composition of wherein the second active agent is doxorubicin and the concentration of doxorubicin is about 50 nM to about 5 μM.10. The composition of wherein the second active agent is tamoxifen and the concentration of tamoxifen is about 5 μM to about 50 μM.11. The composition of wherein the second active agent is cisplatin and the concentration of cisplatin is about 5 μM to about 150 μM claim 1 , the second active agent is carboplatin and the concentration of carboplatin is about 5 μM to about 150 μM.12. The composition of wherein the second active agent is paclitaxel and the concentration of paclitaxel is about 0.5 nM to about 5 nM.13. A method of inhibiting the growth or proliferation of cancer cells comprising contacting cancer cells with ...

COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand. 2. The compound of claim 1 , wherein two of R claim 1 , R claim 1 , R claim 1 , and Reach is a halide.3. The compound of claim 1 , wherein two of R claim 1 , R claim 1 , R claim 1 , and Reach is Cl.4. The compound of claim 1 , wherein the remaining two of R claim 1 , R claim 1 , R claim 1 , and Reach is ammonia.5. The compound of claim 1 , wherein at least one of the remaining two of R claim 1 , R claim 1 , R claim 1 , and Ris an amine.6. The compound of claim 1 , wherein the remaining two of R claim 1 , R claim 1 , R claim 1 , and Rjoined together form a diamine.7. The compound of claim 1 , wherein the remaining two of R claim 1 , R claim 1 , R claim 1 , and Rjoined together form cyclohexane-1 claim 1 ,2-diamine.9. The compound of claim 1 , wherein Rand Rare different.11. The compound of claim 1 , wherein Ris alkyl or cycloalkyl.12. The compound of claim 1 , wherein Ris alkyl optionally substituted with one or more groups each independently selected from halogen claim 1 , hydroxyl claim 1 , ester claim 1 , alkoxy claim 1 , aryloxy claim 1 , amino claim 1 , amide claim 1 , aryl claim 1 , arylalkyl claim 1 , cycloalkyl claim 1 , heteroaryl claim 1 , and heterocyclyl claim 1 , wherein each of ester claim 1 , alkoxy claim 1 , aryloxy claim 1 , amino claim 1 , amide claim 1 , aryl claim 1 , arylalkyl claim 1 , cycloalkyl claim 1 , heteroaryl claim 1 , and heterocyclyl optionally is substituted with one or more suitable substituents.13. The compound of claim 12 , wherein Ris alkyl optionally substituted with one or more groups each independently selected from halogen claim 12 , hydroxyl claim 12 , alkoxy claim 12 , aryloxy claim 12 , arylalkoxy claim 12 , amino claim 12 , amide claim 12 , and aryl claim 12 , wherein each of alkoxy claim 12 , aryloxy claim 12 , ...

THE USE OF A TEMPORARY INHIBITOR OF P53 FOR PREVENTING OR REDUCING CANCER RELAPSE

The present invention relates to a temporary inhibitor of p53 for its use for preventing or reducing cancer relapse in cancer patients. 1. A method for preventing or reducing cancer relapse in a cancer patient in need thereof comprising administering , to the cancer patient , a temporary inhibitor of p53.2. The method according to claim 1 , wherein the temporary inhibitor of p53 is used in combination with an anti-cancer treatment.3. The method according to claim 2 , wherein the temporary inhibitor of p53 and the anti-cancer agent are each separately administered to the cancer patient.4. The method according to claim 2 , wherein the temporary inhibitor of p53 is administered previously to the anti-cancer agent.5. The method according to claim 2 , wherein the administration of the temporary inhibitor of p53 to the cancer patient is interrupted previously to stopping the administration of the anti-cancer agent.6. The method according to claim 2 , wherein the temporary inhibitor of p53 and the anti-cancer agent are concomitantly administered to the cancer patient.7. The method according to claim 2 , wherein the temporary inhibitor of p53 and the anti-cancer agent are combined in a single pharmaceutical composition which is administered to the cancer patient.8. (canceled)9. The method according to claim 2 , wherein the anticancer agent is a platinum anticancer drug.10. The method according to claim 2 , wherein the anticancer agent is cisplatin or a cisplatin derivative or a cisplatin complex.11. The method according to claim 2 , wherein the temporary inhibitor of p53 is pifithrin-alpha claim 2 , pifithrin-μ claim 2 , or cyclic pifithrin-alpha hydrobromide.12. The method according to claim 2 , wherein the cancer patients are patient is affected with breast cancer.13. The method of claim 9 , wherein the platinum anticancer drug is cisplatin claim 9 , carboplatin claim 9 , oxaliplatie claim 9 , nédaplatin claim 9 , satraplatin claim 9 , picoplatin claim 9 , ...

DRUG DELIVERY COMPOSITIONS AND METHODS

One aspect of the present invention is directed to conjugates that comprise a linear polymer carrier, a linker and one or more drugs or imaging agents, as well as pharmaceutical compositions that include such conjugates. The drug may be a platinum-containing drug with a linker comprised of a modified amino acid. The conjugate may alternatively include a metal complexing ligand with a metal used for imaging or chemotherapeutic purposes. Another aspect of the invention is directed to formulations and processes for lyophilization of hyaluronan conjugates. Another aspect of the invention is directed to methods for treating and/or inhibiting cancer utilizing the conjugates and compositions described herein. 1. A composition comprising: hyaluronan;', 'a chelated platinum; and', 'a linker joining the hyaluronan and the platinum,', 'wherein the linker comprises an amine, amide or carboxyl group capable of chelating the platinum., 'a drug conjugate, the drug conjugate comprising2. The composition of claim 1 , wherein the linker comprises at least two groups selected from the group consisting of amine claim 1 , amide and carboxyl claim 1 , wherein each of the two groups may be the same or different.3. The composition of claim 1 , wherein the linker comprises a modified amino acid capable of chelating the platinum.4. The composition of claim 3 , wherein the linker comprises one or two modified amino acids.5. The composition of claim 4 , wherein the linker comprises a derivative of lysine.6. The composition of claim 5 , wherein the derivative of lysine is N-acetyl lysine.7. The composition of claim 1 , wherein the linker comprises a ligand selected from the group consisting of diglycine claim 1 , dicarboxylato claim 1 , maloyl claim 1 , and diamino.8. The composition of claim 1 , wherein the linker comprises HOOC—X—NH—Y claim 1 ,{'sub': 2', '2', '2, 'wherein X is selected from the group consisting of CH, CHZ, and CHZCH,'}wherein Z is an aliphatic group, andwherein Y is a moiety ...

Method of Treating Cancer by Inhibition of DNA Repair Proteins

Methods of treating cancer using antisense oligonucleotides directed against DNA double-strand break repair proteins such as BRCA2 or RAD51 are provided. The antisense oligonucleotides can he used alone, in tandem or in combination with other cancer therapies, in particular with therapies that lead to DNA damage, inhibition of DNA repair or inhibition of DNA synthesis, such as radiation, platinum drugs, alkylating agents, PARP inhibitors, or inhibitors of thymidylate synthase. 147-. (canceled)48. A method of treating cancer in a subject comprising administering to the subject an effective amount of an antisense oligonucleotide comprising a sequence complementary to an mRNA encoding a DNA double strand break repair protein , wherein the antisense oligonucleotide has a length between 7 and 100 nucleotides in length , between about 12 and about 50 nucleotides , between about 12 and 35 nucleotides or between about 12 and 30 nucleotides.49. The method according to claim 48 , wherein the mRNA encodes BRCA2 or RAD51.50. The method according to claim 48 , wherein the antisense oligonucleotide comprises (a) at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs: 1 claim 48 , 2 claim 48 , 3 claim 48 , 13 claim 48 , 14 or 15; (b) at least 10 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs: 1 claim 48 , 2 claim 48 , 3 claim 48 , 13 claim 48 , 14 or 15; or (c) the sequence as set forth in any one of SEQ ID NOs: 1 claim 48 , 2 claim 48 , 3 claim 48 , 13 claim 48 , 14 or 15.51. The method according to claim 48 , wherein the antisense oligonucleotide comprises (a) one or more phosphorothioate bonds; (b) one or more 2′-O-methyl modified nucleotides; (c) one or more 2′-O-methoxyethyl (2′-MOE) modified nucleotides; or (d) both RNA and DNA nucleotides.52. The method according to claim 48 , wherein the antisense oligonucleotide is a gapmer antisense oligonucleotide.53. The method according to claim 48 , wherein the cancer ...

SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 2. (canceled)3. A method for the treatment of a disease of uncontrolled cell growth claim 1 , proliferation or survival claim 1 , an inappropriate cellular immune response claim 1 , or an inappropriate cellular inflammatory response claim 1 , particularly in which the uncontrolled cell growth claim 1 , proliferation and/or survival claim 1 , inappropriate cellular immune response claim 1 , or inappropriate cellular inflammatory response is mediated by the mitogen-activated protein kinase (MEK-ERK) pathway claim 1 , more particularly in which the disease of uncontrolled cell growth claim 1 , proliferation and/or survival claim 1 , inappropriate cellular immune response claim 1 , or inappropriate cellular inflammatory response is a haemotological tumour claim 1 , a solid tumour and/or metastases thereof claim 1 , e.g. Leukaemias and myelodysplastic syndrome claim 1 , malignant lymphomas claim 1 , head and neck tumours including brain tumours and brain metastases claim 1 , tumours of the thorax including non-small cell and small cell lung tumours claim 1 , gastrointestinal tumours claim 1 , endocrine tumours claim 1 , mammary and other gynaecological tumours claim 1 , urological tumours including renal claim 1 , bladder and prostate tumours claim 1 , skin tumours claim 1 , and sarcomas claim 1 , and/or metastases thereof comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to or a stereoisomer claim 1 , a tautomer claim 1 , an N-oxide claim 1 , a hydrate claim 1 , a ...

MicroRNA-based methods and assays for osteocarcinoma

Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma. 127-. (canceled)1. A method of treating osteosarcoma , comprising administering to a subject in need thereof an effective amount of an antisense molecule specific for microRNA (miRNA) chosen from miR-1 and miR-10b , thereby treating the osteosarcoma.228. The method of claim , wherein the antisense molecule is stabilized RNA.329. The method of claim , wherein the stabilized RNA is a locked nucleic acid (LNA). oligonucleotide.4128. The method of claim , wherein the antisense molecule is DNA.4228. The method of claim , wherein the antisense molecule is 20-30 nucleotides long and comprises a nucleotide sequence at least 90 percent identical to any one of the nucleic acid sequences consisting of a group SEQ ID NO:4; SEQ ID NO:7; and SEQ ID NO:10 (all antisense to miR-1).43. The method of claim 42 , wherein the antisense molecule is 20-30 nucleotides long and comprises a nucleotide sequence at least 90 percent identical SEQ ID NO:4.44. The method of claim 42 , wherein the antisense molecule is 20-30 nucleotides long and comprises a nucleotide sequence at least 90 percent identical SEQ ID NO:7.45. The method of claim 42 , wherein the antisense molecule is 20-30 nucleotides long and comprises a nucleotide sequence at least 90 percent identical SEQ ID NO:10.46. The method of claim 42 , wherein the sequence of the antisense molecule comprises any one of the nucleotide sequences SEO ID NO:4; SEQ ID NO:7; and SEQ ID NO:10.4728. The method of claim claim 42 , wherein the antisense molecule is 20-30 nucleotides long and ...

TREATMENT WITH ANTI-VEGF ANTIBODIES

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. 1. A method of treating cancer in a human patient , comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-neoplastic composition , wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent.2. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer claim 1 , colorectal cancer claim 1 , rectal cancer claim 1 , non-small cell lung cancer claim 1 , non-Hodgkins lymphoma (NHL) claim 1 , renal cell cancer claim 1 , prostate cancer claim 1 , liver cancer claim 1 , pancreatic cancer claim 1 , soft-tissue sarcoma claim 1 , kaposi's sarcoma claim 1 , carcinoid carcinoma claim 1 , head and neck cancer claim 1 , melanoma claim 1 , ovarian cancer claim 1 , mesothelioma claim 1 , and multiple myeloma.3. The method of claim 1 , wherein the cancer is metastatic.4. The method of claim 1 , wherein the patient is previously untreated.5. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents claim 1 , antimetabolites claim 1 , folic acid analogs claim 1 , pyrimidine analogs claim 1 , purine analogs and related inhibitors claim 1 , vinca alkaloids claim 1 , epipodopyyllotoxins claim 1 , antibiotics claim 1 , L-Asparaginase claim 1 , topoisomerase inhibitor claim 1 , interferons claim 1 , platinum cooridnation complexes claim 1 , anthracenedione substituted urea claim 1 , methyl hydrazine derivatives claim 1 , adrenocortical suppressant claim 1 , adrenocorticosteroides claim 1 , progestins claim 1 , estrogens claim 1 , antiestrogen claim 1 , androgens claim 1 , antiandrogen claim 1 ...

APPARATUS FOR TREATING PATHOLOGICAL CELLS

An electromagnetic field generating apparatus for treating pathological cells, in particular with tumor suppression function. The ratio of static magnetic field to alternating magnetic field is in the range of 0.5-2.5, and the total intensity is in the range up to 100 mT. It provides non-invasive low toxicity and side effects, significantly inhibiting a plurality of tumors, influencing the intracellular superoxide radical content, and promoting cell autophagy. The mechanism of action of the magnetic field is on the electron spin energy levels and consequently on the free radicals concentration. Additional magnetic field having frequency up to 100 MHz and intensity down to microTesla range can be also used to improve the antitumor efficacy in combination with the static as well as the extremely low frequency electromagnetic field (1-300 Hz) influencing the spin hyperfine resonance. A combination method is also provided of a power-frequency electromagnetic field generating device and a platinum-based medicine. The in vitro and in vivo experiments confirmed that the tumor therapeutic electromagnetic field combined with platinum-based chemotherapy drugs can enhance the efficacy of platinum-based chemotherapy drugs and magnetic field alone, a significant inhibition of a variety of tumors; can reduce the dose of cisplatin and reduce side effects. 1867812671267. Apparatus for treating pathological cells , neuroblastoma and nephroblastoma type , comprising a workspace () configured to receive a target body , at least one set of coils ( , ) arranged to irradiate a static electromagnetic field in said workspace and also arranged to irradiate an alternating magnetic field in said workspace () , a control unit () arranged to supply selectively current to said at least one set of coils ( ,) in such a way to irradiate in said workspace a static electromagnetic field and an alternating magnetic field for predetermined time intervals T1 , T2 , T3 , . . . Tn , said control unit () ...

Targeted conjugates encapsulated in particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

METHOD FOR MANUFACTURING DRUG-CONTAINING BIODEGRADABLE FIBER MATERIAL BY ELECTROSPINNING

The present invention addresses the problem of providing a drug formulation material with which localized sustained release of a drug at any site in the body is possible, and which has good bioabsorption and is absorbed and broken down by the body after sustained release of the drug. A drug formulation material that has an exceedingly high sustained release effect, and that solves the foregoing problem, was successfully developed by dissolving a biodegradable resin and a drug in a solvent to prepare a spinning solution, and spinning fibers from the spinning solution by electrospinning. 1. A bioabsorbable cotton-like material having a cotton- or nonwoven fabric-like structure , comprising a fibrous material that comprises a drug and a biodegradable resin and has an average outer diameter of 1 μm or more but 150 μm or less.2. The bioabsorbable cotton-like material according to claim 1 , wherein the fibrous material has an average molecular weight of 50 claim 1 ,000 or more but less than 1 claim 1 ,000 claim 1 ,000.3. The bioabsorbable cotton-like material according to claim 1 , whose bulk density is 0.01 g/cmto 0.1 g/cm.4. The bioabsorbable cotton-like material according to claim 1 , wherein the biodegradable resin is PLGA or a copolymer thereof.5. The bioabsorbable cotton-like material according claim 1 , wherein the drug is an anticancer agent.6. The bioabsorbable cotton-like material according to claim 1 , which has been subjected to sterilization treatment.7. A method for manufacturing a bioabsorbable cotton-like material claim 1 , comprising:step 1) dissolving a biodegradable resin and a drug in a solvent to prepare a spinning solution; andstep 2) spinning fibers from the spinning solution by electrospinning.8. The method of claim 7 , wherein in the step 2) claim 7 , the fibers are spun by electrospinning by applying a voltage between a nozzle part provided on a spinning solution extrusion side and a plate placed in an ethanol bath provided on a collector side to ...

KITS AND METHODS FOR TREATING CANCERS

A kit containing a crystalline form of a quinazoline compound. More particularly, the crystalline form is derived from the compound of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one. Also disclosed is a method of treating cancers with the crystalline form or a kit thereof. 2. The kit of claim 1 , wherein the chemical purity of the crystalline form is greater than 95%.3. The kit of claim 1 , wherein the crystalline form is as described in (a).4. The kit of claim 1 , wherein the crystalline form is as described in (b).5. The kit of claim 1 , wherein the crystalline form is as described in (c).6. The kit of claim 1 , wherein the crystalline form is as described in (d).7. The kit of claim 1 , wherein the crystalline form is as described in (e).8. The kit of claim 1 , wherein the crystalline form is as described in (a) claim 1 , and wherein the crystalline form has a C solid state nuclear magnetic resonance (ssNMR) spectrum comprising peaks at the following chemical shifts: 147.7±0.5 claim 1 , 156.2±0.5 and 165.4±0.5 ppm.9. The kit of claim 1 , wherein the crystalline form is as described in (b) claim 1 , and wherein the crystalline form has a C ssNMR spectrum comprising peaks at the following chemical shifts: 54.3±0.5 claim 1 , 127.3±0.5 claim 1 , 146.9±0.5 and 156.7±0.5 ppm.10. The kit of claim 1 , wherein the crystalline form is as described in (c) claim 1 , and wherein the crystalline form has a C ssNMR spectrum comprising peaks at the following chemical shifts: 129.2±0.5 claim 1 , 153.1±0.5 claim 1 , 156.7±0.5 and 165.2±0.5 ppm.11. The kit of claim 1 , wherein the crystalline form is as described in (d) claim 1 , and wherein the crystalline form has a C ssNMR spectrum comprising peaks at the following chemical shifts: 145.8±0.5 claim 1 , 157.8±0.5 and 164.5±0.5 ppm.12. The kit of claim 1 , wherein the crystalline form is as described in (e) claim 1 , and wherein the crystalline form has a C ssNMR spectrum ...

COMPOSITION COMPRISING AN ALGAL PROTEOGLYCAN EXTRACT AND USE THEREOF

Use of an algal proteoglycan extract and a composition comprising the same in the manufacture of a medicament for treating or preventing tumor, pain, inflammation or diseases mediated by inflammatory factors. 17-. (canceled)8. A method for treating or preventing pancreatic cancer , pain , inflammation , or diseases mediated by inflammatory factors in a subject , comprising administering a therapeutically or prophylactically effective amount of an algal proteoglycan extract or a composition comprising the algal proteoglycan extract to the subject , wherein the pain is preferably tumor-associated pain , and wherein the inflammation is preferably tumor-associated inflammation.9. (canceled)10. (canceled)11. A pharmaceutical composition comprising an algal proteoglycan extract and one or more of other anti-tumor agents.12. The pharmaceutical composition according to claim 11 , wherein the anti-tumor agents are nucleotide synthesis inhibitors claim 11 , such as 5-fluorouracil (5-FU); platinum compounds claim 11 , such as carboplatin; alkylating agents claim 11 , such as cyclophosphamide and nitrosoureas; DNA polymerase inhibitors claim 11 , such as gemcitabine; agents interfering with protein synthesis claim 11 , such as etoposide (VP-16); anti-tumor antibiotics claim 11 , such as adriamycin (ADM) claim 11 , and the like.13. (canceled)14. (canceled)15. A Method for treating or preventing tumor in a subject comprising administering a therapeutically or prophylactically effective amount of the pharmaceutical composition according to to the subject.16. The method according to claim 15 , wherein the pharmaceutical composition comprising an algal proteoglycan extract and one or more of other anti-tumor agents is administered via any appropriate route claim 15 , such as orally claim 15 , subcutaneously claim 15 , intramuscularly or intraperitoneally; preferably claim 15 , the algal proteoglycan extract is administered orally claim 15 , and the one or more of other anti-tumor ...

Methods and materials for assessing loss of heterozygosity

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

MUTANT GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (GAPDH) COMPOSITIONS AND METHODS OF TREATING CANCER

Provided herein are compositions comprising mutant GADPH. Methods for treating or preventing cancer in a subject by administering to the subject a therapeutically effective amount of mutant GAPDH compositions are provided. 1. An isolated nucleic acid molecule which encodes a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) , said GAPDH comprises at least one mutation.2. The isolated nucleic acid molecule according to claim 1 , wherein the GAPDH has at least two claim 1 , three claim 1 , four claim 1 , five claim 1 , or six mutations.3. The isolated nucleic acid molecule according to claim 1 , wherein the GAPDH has at least one mutation claim 1 , said mutation is an Arginine to Glutamine at position 13 (R13Q).4. The isolated nucleic acid molecule according to claim 1 , wherein the GAPDH has at least one mutation claim 1 , said mutation is an Aspartic Acid to Glutamic Acid at position 39 (D39E).5. The isolated nucleic acid molecule according to claim 1 , wherein the GAPDH comprises a nucleotide sequence having at least 80% identity to the nucleotide sequence set forth in SEQ ID NO: 3 or 5.6. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 1 , in combination with a pharmaceutically acceptable carrier or adjuvant.7. An isolated polypeptide molecule comprising a mutant GAPDH claim 1 , said GAPDH comprises at least one mutation.8. The isolated polypeptide molecule according to claim 7 , wherein the GAPDH has at least two claim 7 , three claim 7 , four claim 7 , five claim 7 , or six mutations.9. The isolated polypeptide molecule according to claim 7 , wherein the GAPDH has at least one mutation claim 7 , said mutation is an Arginine to Glutamine at position 13 (R13Q).10. The isolated polypeptide molecule according to claim 7 , wherein the GAPDH has at least one mutation claim 7 , said mutation is an Aspartic Acid to Glutamic Acid at position 39 (D39E).11. The isolated polypeptide molecule according to claim 7 , wherein the GAPDH ...

Methods of treating cancer with an anti-pd-l1 antibody

The present disclosure relates to methods, uses, and kits related to treating cancers by administering an anti-PD-L1 antibody (e.g., atezolizumab) to a patient. In some embodiments, the anti-PD-L1 antibody is administered in 840 mg every 2 weeks or 1680 mg every 4 weeks for two or more cycles.

Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment

This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

ONCOLYTIC VIRUS GROWTH METHOD AND ANTITUMOR AGENT

Provided is antitumor therapy using oncolytic viruses which exhibits an excellent antitumor effect and has reduced adverse effects. 1: An antitumor agent , comprising:a combination of an oncolytic virus and an anticancer agent selected from the group consisting of oxaliplatin, an anticancer plant alkaloid, and an antimetabolite.2: The antitumor agent according to claim 1 , wherein the oncolytic virus is a coxsackievirus or an adenovirus.3: The antitumor agent according to claim 2 , wherein the coxsackievirus is coxsackievirus A11 or coxsackievirus B3.4: The antitumor agent according to claim 1 , wherein the anticancer agent is an anticancer plant alkaloid claim 1 , andthe anticancer plant alkaloid is one or more selected from the group consisting of SN-38, irinotecan, and a salt thereof.5: The antitumor agent according to claim 1 , wherein the anticancer agent is an antimetabolite claim 1 , andthe antimetabolite is 5-FU or a salt thereof.6: The antitumor agent according to claim 1 , comprising:an oncolytic virus and an anticancer agent selected from the group consisting of oxaliplatin, an anticancer plant alkaloid, and an antimetabolite.7: The antitumor agent according to claim 6 , wherein the oncolytic virus is a coxsackievirus or an adenovirus.8: The antitumor agent according to claim 7 , wherein the coxsackievirus is coxsackievirus A11 or coxsackievirus B3.9: The antitumor agent according to claim 6 , wherein the anticancer agent is an anticancer plant alkaloid claim 6 , andthe anticancer plant alkaloid is one or more selected from the group consisting of SN-38, irinotecan, and a salt thereof.10: The antitumor agent according to claim 6 , wherein the anticancer agent is an antimetabolite claim 6 , andthe antimetabolite is 5-FU or a salt thereof.11: The antitumor agent according to claim 1 , which is a kit comprising a drug comprising an oncolytic virus and a drug comprising an anticancer agent selected from the group consisting of oxaliplatin claim 1 , an ...

GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF

The disclosure relates generally to gamma polyglutamated raltitrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated raltitrexed, and methods of making and using the gamma polyglutamated raltitrexed compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). 1. A composition comprising a gamma polyglutamated raltitrexed.2. The composition of claim 1 , wherein the gamma polyglutamated raltitrexed comprises 1-10 glutamyl groups having gamma carboxyl group linkages.3. The composition of or claim 1 , wherein the gamma polyglutamated raltitrexed contains 4 claim 1 , 5 claim 1 , 2-10 claim 1 , 4-6 claim 1 , or more than 5 claim 1 , glutamyl groups having gamma carboxyl group linkages.4. The composition according to any of - claim 1 , wherein the gamma polyglutamated raltitrexed is gamma tetraglutamated raltitrexed.5. The composition according to any of - claim 1 , wherein the gamma polyglutamated raltitrexed is gamma pentaglutamated raltitrexed.6. The composition according to any of - claim 1 , wherein the gamma polyglutamated raltitrexed is gamma hexaglutamated raltitrexed.7. The composition according to any of - claim 1 , wherein(a) the gamma polyglutamated raltitrexed comprises two or more glutamyl groups in the L-form having gamma carboxyl group linkages,(b) each of the glutamyl groups of the gamma polyglutamated raltitrexed is in the L-form and has a gamma carboxyl group linkage,(c) at least one of the glutamyl groups of the gamma polyglutamated raltitrexed is in the D-form and has a gamma carboxyl group linkage,(d) each of the glutamyl groups of the gamma polyglutamated raltitrexed other than the glutamyl group of raltitrexed is in the D-form and has a gamma carboxyl group linkage, or(e) the gamma polyglutamated raltitrexed comprises two or more glutamyl groups in the L-form and at least one glutamyl ...

METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly pancreatic, colorectal, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., gemcitabine and ABRAXANE®; leucovorin, 5-fluorouracil, and irinotecan; and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a pancreatic, colorectal, or endometrial tumor. Also described are methods of treating cancer, particularly pancreatic, colorectal, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer. 162-. (canceled)63. A method of treating platinum-resistant ovarian cancer , platinum-resistant primary peritoneal cancer , or platinum-resistant fallopian cancer in a subject , comprising administering to the subject a therapeutically effective amount of a modified immunoglobulin molecule comprising a first antigen-binding site that specifically binds human VEGF , and a second antigen-binding site that specifically binds human DLL4 , wherein the modified immunoglobulin molecule is administered following prior administration of an anti-VEGF agent.64. The method of claim 63 , wherein the modified immunoglobulin molecule is administered in combination with a taxane.65. The method of claim 64 , wherein the taxane is paclitaxel claim 64 , docetaxel claim 64 , albumin-bound paclitaxel claim 64 , DHA-paclitaxel claim 64 , or PG-paclitaxel.66. The method of claim 63 , wherein the modified immunoglobulin molecule is a monovalent bispecific antibody claim 63 , bivalent bispecific antibody claim 63 , or dual ...

CANCER TREATMENTS

Disclosed herein are compositions comprising nanoparticle complexes comprising albumin-bound paclitaxel and an anti-VEGF antibody, wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25. Additionally disclosed herein are methods using the compositions of the present invention, such as for treating a VEGF-expressing cancer in a mammal, for example, skin cancer. 172-. (canceled)73. A composition comprising nanoparticle complexes comprising:(a) albumin-bound paclitaxel; and(b) an anti-VEGF antibody;wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25.74. The composition of claim 73 , wherein the composition is a dry composition claim 73 , wherein the nanoparticle complexes retain antibody-mediated VEGF binding specificity.75. The composition of claim 73 , wherein the composition comprises an alkylating agent.76. The composition of claim 74 , wherein the composition comprises an alkylating agent.77. The composition of claim 73 , wherein the anti-VEGF antibody is a humanized antibody.78. The composition of claim 73 , wherein the anti-VEGF antibody is bevacizumab.79. A method for treating a VEGF-expressing cancer in a mammal claim 73 , which method comprises:(a) obtaining a dry composition of preformed nanoparticle complexes comprising albumin-bound paclitaxel and an anti-VEGF antibody, wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25;(b) forming an aqueous composition of said dry composition, said aqueous composition being suitable for injection into a mammal having cancer, and (c) administering to said mammal an effective amount of the aqueous composition, wherein said administration treats said cancer and wherein said preformed complexes retain antibody mediated VEGF binding specificity.80. The method of claim 79 , wherein said mammal is a human.81. The method of claim 79 , wherein said cancer is skin cancer.82. The method of claim 81 , wherein said skin cancer is stage IV melanoma.83. The method of ...

IMPLANT COMPOSITIONS FOR THE UNIDIRECTIONAL DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN

The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain. 24-. (canceled)5. The implant of claim 1 , wherein the implant further comprises a drug-permeable claim 1 , hydrophilic layer d) positioned between the drug elution surface of the drug-containing layer and to be positioned proximal to the tissue.68-. (canceled)9. The implant of claim 5 , wherein the layer d) contains a steroid and the drug.10. The implant of claim 9 , wherein the steroid is dexamethasone.11. The implant of claim 1 , wherein the hydrophobic lipid or polymer in layers a) claim 1 , b) claim 1 , and/or c) is a steroid or a fatty acid.12. The implant of claim 11 , wherein the steroid is cholesterol.1315-. (canceled)16. The implant of claim 11 , wherein the fatty acid is stearic acid claim 11 , palmitic acid claim 11 , or a glyceride.1718-. (canceled)19. The implant of claim 16 , wherein the glyceride is a glyceryl behenate or stearin (tristearin).20. (canceled)21. The implant of claim 1 , wherein the hydrophilic polymer present in layer a) and/or d) is a polyether or a polysaccharide.22. The implant of claim 21 , wherein the hydrophilic polymer is a polyethylene oxide claim 21 , polypropylene oxide claim 21 , or a polyethylene glycol.2324-. (canceled)25. The implant of claim 21 , wherein the polysaccharide is chitosan or polyanhydroglucuronic acid.2629-. (canceled)30. The implant of claim 1 , wherein the drug is an anti-cancer compound or a chemotherapeutic.31. (canceled)32. The implant of claim 30 , wherein the chemotherapeutic is temozolomide claim 30 , paclitaxel claim 30 , cetuximab claim 30 , irinotecan claim 30 , everolimus claim 30 , carboplatin claim 30 , or ...

ANTIBODIES TO INTERLEUKIN-6 AND USE THEREOF

The present disclosure provides antibodies that bind to human interleukin-6 (IL6). The antibodies can modulate IL6 signaling and thus used in treatment or prevention of IL6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (RA), angiogenesis, and cancer. 1. An isolated antibody that binds to human interleukin 6 (IL6) , comprising:{'sub': 's', '(a) a heavy chain variable region (V), which comprises a heavy chain complementary determining region 1 (HC CDR1) of SEQ ID NO: 2, a heavy chain complementary determining region 2 (HC CDR2) of SEQ ID NO: 4, and a heavy chain complementary determining region 3 (HC CDR3) of SEQ ID NO: 6 or SEQ ID NO: 16; or'}{'sub': 'L', '(b) a light chain variable region (V), which comprises a light chain complementary determining region 1(LC CDR)1 of SEQ ID NO: 9, a light chain complementary determining region 2 (LC CDR2) of SEQ ID NO: 11, and a light chain complementary determining region 3 (LC CDR3) of SEQ ID NO: 13 or SEQ ID NO: 15.'}2. The isolated antibody of claim 1 , which comprises (i) a Vthat comprises the HC CDR1 of SEQ ID NO: 2 claim 1 , the HC CDR2 of SEQ ID NO: 4 claim 1 , and the HC CDR3 of SEQ ID NO: 6; or (ii) a Vthat comprises the HC CDR1 of SEQ ID NO: 2 claim 1 , the HC CDR2 of SEQ ID NO: 4 claim 1 , and the HC CDR3 of SEQ ID NO: 16.3. The isolated antibody of claim 2 , which comprises a Vthat comprises the amino acid sequence of SEQ ID NO:17 or SEQ ID NO:18.4. The isolated antibody of claim 2 , which further comprises (i) a Vthat comprises the LC CDR1 of SEQ ID NO: 9 claim 2 , the LC CDR2 of SEQ ID NO: 11 claim 2 , and the LC CDR3 of SEQ ID NO: 13; or (ii) a Vthat comprises the LC CDR1 of SEQ ID NO: 9 claim 2 , the LC CDR2 of SEQ ID NO: 11 claim 2 , and the LC CDR3 of SEQ ID NO: 15.5. The isolated antibody of claim 4 , which comprises a Vthat comprises the amino acid sequence of SEQ ID NO:19 or SEQ ID NO:20.6. The isolated antibody of claim 1 , which is selected from the group ...

COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF

This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. 125-. (canceled)27. The composition of claim 26 , wherein the compound of formula I is triciribine.28. The composition of claim 26 , wherein the compound of formula I is triciribine phosphate.29. The composition of claim 26 , wherein the compound of formula I is triciribine phosphonate.30. The composition of claim 26 , wherein the compound of formula I is present in a dose amount of at least 20 mg/m.31. The composition of claim 26 , wherein the compound of formula I is present in an amount of at least 10 mg/m.32. The method of claim 26 , wherein the administration is parenteral administration.33. The method of claim 32 , wherein the parenteral administration is intravenous administration.34. The method of claim 26 , wherein the administration is oral administration.35. The method of claim 26 , suitable for intravenous administration.36. The method of claim 26 , wherein the one or more platinum compounds is present in a dose about 0.1 mg/mto about 200 mg/m.37. The method of claim 26 , wherein the one or more platinum compounds is present in a dose about 1 mg/mto about 150 mg/m.38. The method of claim 26 , wherein the one or more platinum compounds is present in a dose about 10 mg/mto about 100 mg/m.39. The composition of claim 26 , wherein the one or more platinum compounds is present in a dose about 25 mg/mto about 50 mg/m.40. The method of claim 26 , wherein the administration of a compound of formula I and the one or more platinum compounds is concurrently administered.41. The method of claim 26 , wherein the administration of a compound of formula I is followed by the administration of the one or more platinum compounds.42. The method of claim 26 , wherein the administration of the ...

Bacterial ghosts for the treatment of cancer

The present invention relates to a composition comprising Bacterial Ghosts, optionally an active agent, and a pharmaceutically acceptable carrier and/or excipient for use in the treatment of cancer.